Chloroquine diphosphate

Name: Chloroquine diphosphate
Brand: Selleck Chemicals
SKU: S4157
Rating: 5 (130 reviews)

For research use only.

Catalog No.S4157

130 publications

Chloroquine diphosphate Chemical Structure

CAS No. 50-63-5

Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).

Selleck's Chloroquine diphosphate has been cited by 130 publications

Theranostics, 2021, 11(2):700-714

PubMed: 33391500 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):65

PubMed: 33431801 ( click the link to review the publication )

Antiviral Res, 2021, 185:104996

PubMed: 33309540 ( click the link to review the publication )

Antiviral Res, 2021, 187:105015

PubMed: 33444702 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2020.1740529

PubMed: 32164484 ( click the link to review the publication )

Autophagy, 2020, 22:1-10

PubMed: 32286915 ( click the link to review the publication )

EMBO Rep, 2020, 6;21(5):e49232

PubMed: 32239622 ( click the link to review the publication )

Aging Cell, 2020, 19(6):e13163

PubMed: 32475059 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):427

PubMed: 32513919 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):712

PubMed: 32873786 ( click the link to review the publication )

Cell Death Dis, 2020, 21;11(2):141

PubMed: 32081881 ( click the link to review the publication )

Cell Death Dis, 2020, 7;11(5):337

PubMed: 32382017 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):103

PubMed: 32029706 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001295R

PubMed: 33103304 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001413R

PubMed: 32860638 ( click the link to review the publication )

Cell Chem Biol, 2020, 19 pii: S2451-9456(20)30078-7

PubMed: 32243810 ( click the link to review the publication )

J Mol Med (Berl), 2020, 10.1007/s00109-020-01971-2

PubMed: 32897390 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:2015920

PubMed: 32908624 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1232816

PubMed: 33062133 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:8345246

PubMed: 33123317 ( click the link to review the publication )

J Cell Physiol, 2020, 24

PubMed: 32329068 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15813

PubMed: 33150736 ( click the link to review the publication )

Neuropharmacology, 2020, 168:108028

PubMed: 32151646 ( click the link to review the publication )

Biochem Pharmacol, 2020, 12:114023

PubMed: 32413426 ( click the link to review the publication )
Sci Rep, 2020, 10(1):614

PubMed: 31953486 ( click the link to review the publication )

Phytomedicine, 2020, 80:153394

PubMed: 33130472 ( click the link to review the publication )

J Biomed Sci, 2020, 27(1):42

PubMed: 32169072 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

J Cardiovasc Transl Res, 2020, 10.1007/s12265-020-10075-8

PubMed: 33025271 ( click the link to review the publication )

Exp Eye Res, 2020, S0014-4835(20)30624-2

PubMed: 33227296 ( click the link to review the publication )

Toxicol In Vitro, 2020, 27;66:104837

PubMed: 32229166 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:9235-9244

PubMed: 32982310 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2020, gmaa097

PubMed: 33085742 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):551-560

PubMed: 32537026 ( click the link to review the publication )

Anticancer Drugs, 2020, 31(6):601-608

PubMed: 32011366 ( click the link to review the publication )

Pharmazie, 2020, 75(6):255-260

PubMed: 32539921 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Viruses, 2020, 12(7):E756

PubMed: 32674313 ( click the link to review the publication )

Theranostics, 2020, 10(5):1981-1996

PubMed: 32104496 ( click the link to review the publication )

BMC Complement Med Ther, 2020, 20(1):194

PubMed: 32576183 ( click the link to review the publication )

bioRxiv, 2020, 2020.10.02.324228

PubMed: 33024968 ( click the link to review the publication )

Vet Microbiol, 2020, 250:108860

PubMed: 33045632 ( click the link to review the publication )

Virol Sin, 2020, 10.1007/s12250-020-00320-4

PubMed: 33237393 ( click the link to review the publication )

Commun Biol, 2020, 13;3(1):25

PubMed: 31932716 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(3):2084-2100

PubMed: 32017705 ( click the link to review the publication )

Antiviral Res, 2020, 183:104933

PubMed: 32949635 ( click the link to review the publication )
Cell Death Dis, 2020, 11(7):539

PubMed: 32681018 ( click the link to review the publication )

mBio, 2020, 11(4):e01833-20

PubMed: 32820005 ( click the link to review the publication )

Adv Ther (Weinh), 2020, 2000034

PubMed: 32838027 ( click the link to review the publication )

Sci Adv, 2019, 5(10):eaax7142

PubMed: 31681849 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Theranostics, 2019, 9(26):8392-8408

PubMed: 31754404 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0236-y

PubMed: 31076723 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32395

PubMed: 31081930 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 456:49-58

PubMed: 31004702 ( click the link to review the publication )

Cell Death Dis, 2019,

PubMed: 30886151 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(15):5769-5785

PubMed: 31409760 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):118

PubMed: 30987681 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2019, 169:266-272

PubMed: 30453174 ( click the link to review the publication )

Front Oncol, 2019, 9:436

PubMed: 31192135 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:179

PubMed: 31337986 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1460

PubMed: 31920653 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114781

PubMed: 31618659 ( click the link to review the publication )

Int J Oncol, 2019, 54(5):1625-1638

PubMed: 30896863 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):756-767

PubMed: 30145802 ( click the link to review the publication )

Am J Transl Res, 2019, 11(2):931-941

PubMed: 30899392 ( click the link to review the publication )

Oncol Rep, 2019, 41(5):2803-2817

PubMed: 30864717 ( click the link to review the publication )
Biochem Biophys Res Commun, 2019, 510(2):278-283

PubMed: 30686534 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1270-1277

PubMed: 31113618 ( click the link to review the publication )

AMB Express, 2019, 9(1):108

PubMed: 31309361 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(11):1053-1060

PubMed: 31407376 ( click the link to review the publication )

Breast Cancer (Dove Med Press), 2019, 11:231-241

PubMed: 31839713 ( click the link to review the publication )

Molecules, 2019, 24(15)

PubMed: 31357480 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4295

PubMed: 30327467 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):215

PubMed: 30180906 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):702

PubMed: 29899555 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29568063 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):556

PubMed: 29748581 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10923

PubMed: 30026540 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:887-897

PubMed: 29740218 ( click the link to review the publication )

Int J Oncol, 2018, 53(1):215-224

PubMed: 29693166 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):2200-2212

PubMed: 30106132 ( click the link to review the publication )

Toxicology, 2018, 406-407:114-122

PubMed: 30053495 ( click the link to review the publication )

Am J Transl Res, 2018, 10(4):1229-1236

PubMed: 29736216 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2206-2214

PubMed: 30066934 ( click the link to review the publication )

Drug Des Devel Ther, 2018, 12:2413-2421

PubMed: 30122899 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2339-2349

PubMed: 29667627 ( click the link to review the publication )

Cancer Lett, 2018, 436:129-138

PubMed: 30118840 ( click the link to review the publication )
J Exp Clin Cancer Res, 2018, 37(1):221

PubMed: 30200999 ( click the link to review the publication )

Front Immunol, 2018, 9:1245

PubMed: 29922290 ( click the link to review the publication )

Mol Immunol, 2018, 99:115-123

PubMed: 29763880 ( click the link to review the publication )

J Cell Biochem, 2018, 10.1002/jcb.27788

PubMed: 30320898 ( click the link to review the publication )

Platelets, 2018, 29(7):695-701

PubMed: 28984160 ( click the link to review the publication )

Arch Virol, 2018, 163(3):623-632

PubMed: 29177545 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12020-12034

PubMed: 29552290 ( click the link to review the publication )

Leukemia, 2017, 10.1038/leu.2016.325

PubMed: 27857131 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):162

PubMed: 29145888 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006321

PubMed: 28394926 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3015

PubMed: 28837148 ( click the link to review the publication )

Br J Cancer, 2017, 117(8):1139-1153

PubMed: 29017179 ( click the link to review the publication )

Sci Rep, 2017, 7:42748

PubMed: 28209994 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:973-982

PubMed: 28292026 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:400

PubMed: 28932708 ( click the link to review the publication )

Int J Mol Med, 2017, 10.3892/ijmm.2017.3008

PubMed: 28560385 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(7):7603-7615

PubMed: 31966605 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):122

PubMed: 28882160 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 42(5):1812-1821

PubMed: 28750364 ( click the link to review the publication )

Biomed Res Int, 2017, 2017:7097580

PubMed: 28706950 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(2):492-498

PubMed: 28320515 ( click the link to review the publication )

Oncotarget, 2017, 8(42):71642-71656

PubMed: 29069735 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2527

PubMed: 28005078 ( click the link to review the publication )
Cell Signal, 2016, 28(8):1086-98

PubMed: 27185187 ( click the link to review the publication )

J Mol Neurosci, 2016, 60(2):205-13

PubMed: 27498200 ( click the link to review the publication )

J Mol Neurosci, 2016, 58(4):401-10

PubMed: 26635026 ( click the link to review the publication )

Arch Biochem Biophys, 2016, 590:37-47

PubMed: 26562437 ( click the link to review the publication )

F1000Res, 2016, 5:150

PubMed: 27134728 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep23056.

PubMed: 26976322 ( click the link to review the publication )

Oncotarget, 2016, 7(41):66360-66385

PubMed: 27626179 ( click the link to review the publication )

J Gen Virol, 2015, 96(12):3484-3492

PubMed: 26459826 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26109433 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description

Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).

Targets

TLR3 ^[4]
()

TLR7 ^[4]
()

TLR8 ^[4]
()

TLR9 ^[4]
()

ATM ^[1]
(Cell-free assay)

In vitro

Chloroquine is a chemotherapeutic agent for the clinical treatment of malaria. Chloroquine is able to bind to DNA, and inhibit DNA replication and RNA synthesis which in turn results in cell death. The effect of Chloroquine may also be related to the formation of a toxic heme-Chloroquine complex. Chloroquine inhibits trophozoite hemoglobin degradation through increasing vacuolar pH and inhibiting the activity of vacuolar phospholipase, vacuolar proteases, and heme polymerase^[1]. Chloroquine possesses definite antirheumatic properties. Chloroquine has immuno-modulatory effects, suppressing the production/release of tumour necrosis factor and interleukin 6. Moreover, Chloroquine exerts direct antiviral effects, inhibiting pH-dependent steps of the replication of several viruses including members of the flaviviruses, retroviruses, and coronaviruses. Its best-studied effects are those against HIV replication^[2]. Chloroquine can accumulate inside the macrophage phagolysosome by ion trapping where it exerts potent antifungal activity against Histoplasma capsulatum and Cryptococcus neoformans by distinct mechanisms. Chloroquine inhibits growth of H. capsulatum by pH-dependent iron deprivation, whereas it is directly toxic to C. neoformans^[3].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human K562 cells	M{OzPGN6fG:2b4jpZ:Kh[XO\|YYm=			NHj4R45EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1\|MT64N{BvVQ>?	NUTZXHZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1N\|g2PjdpPkG4OVM5PTZ5PD;hQi=>
human KB cells	MVfDfZRwfG:6aXRCpIF{e2G7			M1;YdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIJ6KG2rY4LvdIxifGVibXX0bI9lNCCLQ{WwQVAvPiEQvF2=	MlPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR4NEC1NlQoRjF2NkSwOVI1RC:jPh?=
human MDA-MB-468 cells	NI\OeZNEgXSxdH;4bYPDqGG\|c3H5		M{jzc\|Q5KGh?	M{TSRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTDpckBxemW\|ZX7j[UBw\iB\|LkWgeW0hPC1qMj3jbIxwem9vMUDIMZBp\W6xeHH6bY4uOTBveXypMW4tVi2maXX0bJlt[nW2YX6tNU1idWmwZTDofYRzd2OqbH;ybYRmNCCJSUWwQVIvQDFizszN	NF:4b\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm0OVE6Pyd-MUm5OFUyQTd:L3G+
human MCF7 cells	NH;1WY9EgXSxdH;4bYPDqGG\|c3H5		MWm0PEBp	NH;CeWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZkhcW5icILld4Vv[2Vib3[gNE41KHWPIEGtLFEuMDRvKEetdIhmdnmuLUHIMYlucWSjen;bOEw2NWefcYXpco95[Wyrbj22MZltMWKnbor5cElxcXCncnnkbY4uPC27bDmtNWgu[mWwen;b[H1qdWmmYYrvcE0zMDOKKT3vcoUtKEeLNUC9OU42OSEQvF2=	NVfNbolDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OFUyQTdpPkG5PVQ2OTl5PD;hQi=>
human MDA-MB-231 cells	NX\WWoVuS3m2b4TvfIlkyqCjc4PhfS=>		M1S1bVQ5KGh?	NGjlc2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMz61JJVOKDRvKEKtZ4htd3KxLUGwTE1xcGWwb4jhfolvNTFyLYnsLU1PNE5vZHnleIh6dGK3dHHuMVEu[W2rbnWgbJllem:laHzvdoll\SxiR1m1NF03NjB6IN88US=>	M{\6R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUS1NVk4Lz5zOUm0OVE6PzxxYU6=
human HeLa cells	NHzueHJEgXSxdH;4bYPDqGG\|c3H5			M{n4fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgUXRVKGG\|c3H5MEBKSzVyPUOwJO69VQ>?	NH[4RlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1OFMzOid-MkSzOVQ{OjJ:L3G+
human HepG2 cells	Ml22R5l1d3SxeHnjxsBie3OjeR?=		M3TpW\|Q5KGh?	MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUO3MlY5KM7:TR?=	MmTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUWxPFYoRjJ\|OEG1NVg3RC:jPh?=
mammary tumor FM3A	NGjteWREgXSxdH;4bYNqfHliYYPzZZk>			MWDDfZRwfG:6aXPpeJkhd2ZiY3;tdI92dmRid3HzJJRme3SnZDDh[4FqdnO2IH3veZNmKG2jbX3hdpkhfHWvb4KgSm0{SSClZXzsd{whTUN3MDC9JFAvODByMECwN{DPxE1w	NFH4fVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkW3NFM5PSd-MUK1O\|A{QDV:L3G+
red blood cells	NInIWJNCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MkDUOFghcHK\|	M13hS2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGZkSjFxQ3;seY1jcWFiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IIDhdoF{cXSnIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCdM1jdMYh6eG:6YX70bIlv\SCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wNFAyOSEQvF2u	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUe3NEc,OjV4NUm3O\|A9N2F-
red blood cells	M3nJO2FvfGmybHHzcY9lcWGuIHHzd4F6		M1H0S\|Q5KGi{cx?=	MknaRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZTDhcoQheHm{aX3leIhidWmwZT3y[ZNqe3SjboSgdolv\yC\|dHHn[UBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iVkGvV{Bqdm[nY4Tl[EBqdiCqdX3hckBz\WRiYnzvc4Qh[2WubIOgZYZ1\XJiNEigbJJ{NCCLQ{WwJF0hOC5yMEW1JO69VS5?	NHfzNVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKwO\|k{Pyd-MkGyNFc6Ozd:L3G+
red blood cells	MYDBcpRqdWGuYYLpZYwh[XO\|YYm=			MmS3RY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCxdnHs[UBzcW6pIIP0ZYdmKGmwZnXjeIVlKGmwIILl[EBjdG:xZDDj[YxteyCrbjDwdoV{\W6lZTDv[kBCSitiaIXtZY4he2W{dX2gZpkh\HK3ZzDzeZNk\XC2aXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODB5ODFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl\|N{e3PUc,OjB7M{e3O\|k9N2F-
red blood cells	M{XjOWFvfGmvYXzhdolidCCjc4PhfS=>		MWm0PEBpenN?	NGLkfpVCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWg[ZJ6fGi{b3P5eIlkKHO2YXflJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDOSlU1KGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhYzOKXT3ofZBwgGGwdHjpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMEC5OEDPxE1w	M1TyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nki1OVY6Lz5{M{[4OVU3QTxxYU6=
red blood cells	NWfjblE{SW62aX3hcIFzcWGuIHHzd4F6		NYrkPYVQPDhiaILz	NVzxPYtUSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGNjDpcoZm[3SnZDDpckBpfW2jbjDPJJBwe2m2aY\lJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuzTH0ucHmyb4jhcpRpcW6nIIXweIFs\SCjZoTldkA1QCCqcoOsJGlEPTBiPTCwMlAyKM7:TT6=	NGPafGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
red blood cells	M37GWWFvfGmvYXzhdolidCCjc4PhfS=>			NVO0RplWSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGNjDpcoZm[3SnZDDpckBz\WRiYnzvc4Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3hcJN1[XRicnXh[4VvfCCkYYPl[EBNTEhiYYPzZZktKEmFNUCgQUAxNjBzMTFOwG0v	NUPCNoRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlI{OTdpPkK4NlIzOzF5PD;hQi=>
red blood cells	MkD1RY51cW2jbHHybYFtKGG\|c3H5		NFXrO3k4OiCqcoO=	MV7BcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2\|ZX7zbZRqfmViUHzhd41w\Gm3bTDmZYxkcXCjcoXtJFNFPyCrbn\lZ5Rm\CCrbjDoeY1idiC2eYDlJGEueG:\|aYTpeoUhemWmIHLsc49lKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUB{eGWldILvdIhwfG:vZYTybYNidGy7LDDJR\|UxKD1iMD6wNVIh\|ryPLh?=	NVT6O5ZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNVE2PjJpPkK1N\|EyPTZ{PD;hQi=>
red blood cells	MorHRY51cW2jbHHybYFtKGG\|c3H5			Mof0RY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCvYXzhdoli\SC{aX7nJJN1[WenIHnu[oVkfGWmIHnuJJJm\CCkbH;v[EBk\WyuczDpckBxemW\|ZX7j[UBw\iCDQjugbJVu[W5ic3XyeY0h[nliZIL1[{B{fXOlZYD0bYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMEG0JO69VS5?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl\|N{e3PUc,OjB7M{e3O\|k9N2F-
red blood cells	MkDPRY51cXCuYYPtc4Rq[WxiYYPzZZk>		MWm0PEBpenN?	NEG2[VNCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZNmdnOrdHn2[UwhdWWobH;xeYlv\S2{ZYPpd5RidnRicnnu[{B{fGGpZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hTDZiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGGodHXyJFQ5KGi{czygTWM2OCB;IECuNFE1OiEQvF2u	M{LTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkC3PVM4Lz5{MUKwO\|k{PzxxYU6=
red blood cells	MV7BcpRqeGyjc33v[IlidCCjc4PhfS=>		NIrXOXk4OiCqcoO=	M4\OO2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGMUCgbY5n\WO2ZXSgbY4hcHWvYX6gdoVlKGKub3;kJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCyYYLhd4l1\SCuYXP0ZZRmKGSnaInkdo9o\W6jc3WgZZN{[XluIFnDOVAhRSByLkCxOFMh\|ryPLh?=	MmDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7MUe4OVcoRjJ{OUG3PFU4RC:jPh?=
red blood cells	NHHhS5hCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MV20PEBpenN?	NVfoWZJ4SW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDhd4V5fWGuIHXyfZRpem:leYTlJJN1[WenIH;mJINpdG:{b4H1bY5mNXOnboPpeIl3\SCSbHHzcY9lcXWvIH\hcINqeGG{dX2gUmY2PCCrbn\lZ5Rm\CCrbjDoeY1idiC{ZXSgZoxwd2RiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JIxi[3SjdHWg[IVpgWS{b3flcoF{\SCjc4PhfUwhUUN3MDC9JFAvODF4IN88UU4>	NWXzcHhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVY3QDNpPkOwNlk3Pjh\|PD;hQi=>
red blood cells	MYfBcpRqdWGuYYLpZYwh[XO\|YYm=		M1PMclk3KGi{cx?=	MWXBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUh\WG{bImgeJJweGixen;peIUhe3SjZ3Wgc4YhWGyjc33v[Il2dSCoYXzjbZBienWvIFS2JIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{BcO0ifaInwc5hidnSqaX7lJJVxfGGtZTDh[pRmeiB7NjDodpMtKEmFNUCgQUAxNjBzNzFOwG0v	M2\ZclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NES4NlgyLz5{M{S0PFI5OTxxYU6=
FM3A	NHHyNFFHfW6ldHnvckBie3OjeR?=			MkHzV4Vt\WO2aY\peJkh\m:{IF\NN2Eh[2WubIOgc5ZmeiCSbHHzcY9lcXWvIH\hcINqeGG{dX2gZZMhdWWjbjDFR\|UxKHKjdHnvMEBKSzVyIE2gNE4xOTlizszNMi=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjRyOEewPEc,OTJ2MEi3NFg9N2F-
red blood cells	MmXQRY51cW2jbHHybYFtKGG\|c3H5		NIWyUYM1QCCqcoO=	M{LBV2FvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYPlcpNqfGm4ZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hO0R5IHnu[oVkfGWmIHnuJIh2dWGwIF:gdI9{cXSrdnWgdoVlKGKub3;kJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{PIYU1pgXCxeHHueIhqdmVidYD0ZYtmKGGodHXyJFQ5KGi{czygTWM2OCB;IECuNFIh\|ryPLh?=	NXfi[FBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU2QTNpPkKxNVU2PTl\|PD;hQi=>
red blood cells	NUO3cJBYSW62aX3hcIFzcWGuIHHzd4F6		NH\WcYY4OiCqcoO=	M3HE[GFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYPlcpNqfGm4ZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hTDFyIHnu[oVkfGWmIHnuJIh2dWGwIIT5dIUhSS2yb4PpeIl3\SC{ZXSgZoxwd2RiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[2GubImsJGlEPTBiPTCwMlAzKM7:TT6=	NWjlTldyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNVE2PjJpPkK1N\|EyPTZ{PD;hQi=>
red blood cells	MYDBcpRqdWGuYYLpZYwh[XO\|YYm=			NI\zU3BCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCC{aX7nJJN1[WenIGDsZZNud2SrdX2g[oFt[2myYYL1cUA{TDdiaX7m[YN1\WRid3n0bEBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhW1mEUjDHdoVmdiCvZYToc4QtKEmFNUCgQUAxNjB{MzFOwG0v	NH\X[pE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOVYxQCd-MkW3NlU3ODh:L3G+
red blood cells	M2LhXWFvfGmvYXzhdolidCCjc4PhfS=>			NXjYVGg4SW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDveoFt\SC2cn;wbI97d2m2ZTDzeIFo\SCrbn\lZ5Rm\CCrbjDy[YQh[myxb3SgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhSUJtIHj1cYFvKHOncoXtJIJ6KGS{dXegd5V{[2WydHnibYxqfHliYYPzZZktKEmFNUCgQUAxNjB{M{Kg{txONg>?	M2\LNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUO3O\|c6Lz5{MEmzO\|c4QTxxYU6=
red blood cells	M1rQZWFvfGmvYXzhdolidCCjc4PhfS=>			M{TSdWFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTCzSFchSSCrbn\lZ5Rm\CCrbjDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdM1jdbJlxd3ijboTobY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiMkSgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjB{NDFOwG0v	NIjqOJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3OSd-MkS5NFAzPjF:L3G+
red blood cells	M2mxW2FvfGmvYXzhdolidCCjc4PhfS=>		MojoOFghcHK\|	NHLsfGZCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKE6rZ3XybYFvKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC0PEBpenNiYomgX\|NJZS2qeYDvfIFvfGirbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFAvODJ3IN88UU4>	NUPDZZZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFA1PThpPkK4PFAxPDV6PD;hQi=>
red blood cells	NF;0OI9CdnSrcHzhd41w\GmjbDDhd5NigQ>?		NWLtTJBXPDhiaILz	NVHUSHVzSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[U1{\W6\|aYTpeoUhWGyjc33v[Il2dSCoYXzjbZBienWvIEPEO{Bqdm[nY4Tl[EBqdiCqdX3hckBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIIDhdoF{cXSnIHfyc5d1cCCjZoTldkA1QCCqcoOgZpkhUG:nY3jzeEA{OzN2MjDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB{NjFOwG0v	Mn7jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzOUm3NFYoRjNyMUm5O\|A3RC:jPh?=
HCT-8	NVr3fmRbSW62aX3pZ5Jw[mmjbDDhd5NigQ>?		NEO3OpE1QCCqcoO=	NUL1Z3BTSW62aX3pZ5Jw[mmjbDDhZ5Rqfmm2eTDh[4FqdnO2IFPyfZB1d3Oyb4Lp[Il2dSCyYYL2eY0hcW6oZXP0[YQhcW5iaIXtZY4hUEOWLUigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEWOSWPBMEBKSzVyIE2gNE4xOjdizszNMi=>	NGq2WYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5NVI5OCd-MUi1PVEzQDB:L3G+
red blood cells	NGDnfpJCdnSrbXHsZZJq[WxiYYPzZZk>		NXfDVIdEPzJiaILz	NYj0N3lSSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGMUCgbY5n\WO2ZXSgbY4hcHWvYX6geJlx\SCDLYDvd4l1cX[nIILl[EBjdG:xZDDj[YxteyCjc4Pld5Nm\CCjczDwZZJie2m2ZTDsZYN1[XSnIHTlbJllem:pZX7hd4Uh[WO2aY\peJkh[W[2ZYKgO\|IhcHK\|IHL5JJNx\WO2cn;wbI91d22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvODJ7IN88UU4>	NE\DdIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC1OFA{QCd-MkKwOVQxOzh:L3G+
red blood cells	MUDBcpRqdWGuYYLpZYwh[XO\|YYm=		NIXVSI04OiCqcoO=	M1e0S2FvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYPlcpNqfGm4ZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hTDFyIHnu[oVkfGWmIHnuJIh2dWGwIFGtdI9{cXSrdnWgdoVlKGKub3;kJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCuYXP0ZZRmKGSnaInkdo9o\W6jc3WgZZN{[XluIFnDOVAhRSByLkCzJO69VS5?	M1P1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKzNFc1Lz5{MUGyN\|A4PDxxYU6=
red blood cells	NHr5cJZCdnSrbXHsZZJq[WxiYYPzZZk>			NW\wcYFQSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSB\|REegbY5n\WO2ZXSgbY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTXWJTKGe{ZXXuJFEhe3SjaX7pcoch[mG\|ZXSg[ox2d3KxbXX0dolkKGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	MnXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4OUK4N\|EoRjJ5NkmyPFMyRC:jPh?=
3D7	NFzPUWxCdnSrcHzhd41w\GmjbDDhd5NigQ>?			NHnL[2tCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IGDsZZNud2SrdX2g[oFt[2myYYL1cUA{TDdicnnu[{B{fGGpZTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gdIFz[XOrdHXtbYEh[nliTXHsd5RifCCjc4PhfUwhUUN3MDC9JFAvODNizszNMi=>	Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUizNFAoRjJ{OEW4N\|AxRC:jPh?=
red blood cells	NEKye\|dCdnSrbXHsZZJq[WxiYYPzZZk>			NE\2XWlCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gN2Q4SSCrbn\lZ5Rm\CCrbjDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyYYLhd4l1\SCpcn;3eIgh[W[2ZYKgNlQhcHK\|IHL5JHs{UF2qeYDvfIFvfGirbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFAvODN4IN88UU4>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyNkKwNEc,OjV7ME[yNFA9N2F-
red blood cells	MlXDRY51cW2jbHHybYFtKGG\|c3H5			NFXPVVlCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKER4IHnu[oVkfGWmIHnuJIh2dWGwIILl[EBjdG:xZDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heGG{YYPpeIlkKEyGSDDhZ5Rqfmm2eTDifUBO[Wy\|dHH0JJJm[WenboSgZoF{\WRic4DlZ5Rzd3Cqb4TvcYV1emmlIH3leIhw\CxiSVO1NEA:KDBwMESg{txONg>?	MlzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6MEC0OVgoRjJ6OECwOFU5RC:jPh?=
red blood cells	NFvFbFVCdnSrcHzhd41w\GmjbDDhd5NigQ>?			NF:4VVVCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZNmdnOrdHn2[UBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iRE[gbY5n\WO2ZXSgbY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNZYx{fGG2IILlZYdmdnRiYnHz[YQhVESKIHHzd4F6NCCLQ{WwJF0hOC5yNDFOwG0v	NITWdFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6QCd-MkizNVU2QTh:L3G+
red blood cells	MVfBcpRqeGyjc33v[IlidCCjc4PhfS=>			NV[xO2JxSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[U1{\W6\|aYTpeoUhWGyjc33v[Il2dSCoYXzjbZBienWvIFS2JIlv\mWldHXkJIlvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC3NkBpenNiYomgdIFz[XOrdHnjJGxFUCCjc4PhfUwhUUN3MDC9JFAvODRizszNMi=>	MmjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC1NFkoRjJ2OUCwOVA6RC:jPh?=
Vero	MmfBRY51cW2jbHHybYFtKGG\|c3H5		NG\3TIE4OiCqcoO=	Mn3WRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvc3Xud4l1cX[nIGDsZZNud2SrdX2g[oFt[2myYYL1cUBFPiCrbn\lZ5Rm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUApS2W{Y3;wbZRp\WO3czDh[ZRpcW:yczmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCyYYLhd4l1\SCORFigZYN1cX[rdImgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yNTFOwG0v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh\|M{WyNEc,OTl6M{O1NlA9N2F-
red blood cells	MkT0RY51cXCuYYPtc4Rq[WxiYYPzZZk>		M1HYblQhcHK\|	MXTBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYX\0[ZIhPCCqcoOsJGlEPTBiPTCwMlA2PSEQvF2u	NXrHelBrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5PVA5PjVpPkG3PVkxQDZ3PD;hQi=>
red blood cells	NFzTRpJCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MknrOFghcHK\|	M{C2TGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJJJqdmdic4Th[4UhWGyjc33v[Il2dSCoYXzjbZBienWvIEPEO{Bqdm[nY4Tl[EBqdiCqdX3hckBz\WRiYnzvc4Qh[2WubIOgZYZ1\XJiNEigbJJ{NCCLQ{WwJF0hOC5yOEmg{txONg>?	NVn2UlB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNFc6OzdpPkKxNlA4QTN5PD;hQi=>
B-cells	MUTGeY5kfGmxbjDhd5NigQ>?			NEfpZVFEd26lZX70doF1cW:wIILldZVqemWmIH\vdkBp[WyoLX3hfIlu[WxiaX7obYJqfGmxbjDv[kBEeEdvT1TOJIVn\mWldDDvckB1cHmvaXTpcoUhfXC2YXvlJIJ6KFeHSFmgNlMyKG23cnnu[UBDNWOnbHzzJIlvKHSqZTDwdoV{\W6lZTDv[kBidHCqYT3zTYdONixiRVO1NEA:KDBwMUGg{txONg>?	M3Hqc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEC2OlQ5Lz5zMESwOlY1QDxxYU6=
red blood cells	MUTBcpRqeGyjc33v[IlidCCjc4PhfS=>		Mkj2OFghcHK\|	MXfBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nIHHu[EBxgXKrbXX0bIFucW6nIILld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hUzFiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBx[XKjc3n0[UB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JHs{UF1vaInwc5hidnSqaX7lJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUCgQUAxNjF{IN88UU4>	NHXJU489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0OlgyPid-MkW3OFY5OTZ:L3G+
red blood cells	MnXYRY51cXCuYYPtc4Rq[WxiYYPzZZk>		MUS0PEBpenN?	MlXNRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT;wfZJqdWW2aHHtbY5mNXKnc3nzeIFvfCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gT\|EhcW6oZXP0[YQhcW5iaIXtZY4hemWmIHLsc49lKGOnbHzzJIF{e2W\|c3XkJIF{KFt\|SG2tbJlxd3ijboTobY5mKGmwY3;ydI9z[XSrb36gbY5kfWKjdHXkJIZweiB2ODDodpMheHKrb4KgeI8hYzOKXT3ofZBwgGGwdHjpcoUh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNlQhcHK\|IHL5JIxqNCCLQ{WwJF0hOC5zMkWg{txONg>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4OEW0N{c,OjR{Nki1OFM9N2F-
red blood cells	MWPBcpRqdWGuYYLpZYwh[XO\|YYm=			MkjoRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCvYXzhdoli\SC2cn;wbI97d2m2ZTDzeIFo\SCrbn\lZ5Rm\CCrbjDy[YQh[myxb3SgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhSUJtIHj1cYFvKHOncoXtJIJ6KGS{dXegd5V{[2WydHnibYxqfHliYYPzZZktKEmFNUCgQUAxNjF{N{mg{txONg>?	MoPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{e3O\|koRjJyOUO3O\|c6RC:jPh?=
red blood cells	NIq5elZCdnSrbXHsZZJq[WxiYYPzZZk>		MVG0PEBpenN?	Mm\BRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBH[0JzIHnu[oVkfGWmIHnuJIh2dWGwIILl[EBjdG:xZDDj[YxteyCjZoTldkA1QCCqcoOgZpkhYzOKXT3ofZBwgGGwdHjpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMUOyJO69VS5?	NUKzRmtqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFA1PThpPkK4PFAxPDV6PD;hQi=>
red blood cells	NEHOWWlCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MlXXOFghcHK\|	M3;CO2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JJJqdmdic4Th[4UhWGyjc33v[Il2dSCoYXzjbZBienWvIGeyJIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB2ODDodpMtKEmFNUCgQUAxNjF\|ODFOwG0v	MoTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MEe5N\|coRjJzMkC3PVM4RC:jPh?=
red blood cells	MnfIRY51cXCuYYPtc4Rq[WxiYYPzZZk>		NHe5cJA1QCCqcoO=	NEj2TZVCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZJme2m\|dHHueEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iV{KgbY5n\WO2ZXSgbY4hcHWvYX6gdoVlKGKub3;kJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zicnnu[{1{fGGpZTDwZZJie2m2ZTDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KG[ub4egZ5l1d22ndIL5MEBKSzVyIE2gNE4yPCEQvF2u	NIfPdYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK5OVg5Pyd-MkGyPVU5QDd:L3G+
RPMI1640	NEXEcIxCdnSrcHHyZZNqfGmlIHHzd4F6		MnywO\|IhcHK\|	MoX5RY51cXCjcnHzbZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYLld4l{fGGwdDDldpl1cHKxY4n0bYMhe3SjZ3Wgc4YhWGyjc33v[Il2dSCoYXzjbZBienWvIFuxJIlv\mWldHXkJIlvKGi3bXHuJHJRVUlzNkSwJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCQQmSgd5RicW6rbnegZoF{\WRic4DlZ5Rzd3Olb4DpZ{BidmGueYPpd{whUUN3MDC9JFAvOTRizszNMi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{MkKyOkc,OjZ7MkKyNlY9N2F-
red blood cells	M1y5[2FvfGmybHHzcY9lcWGuIHHzd4F6		NIDr[VE1QCCqcoO=	M{XRVWFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWvdJlzcW2ndHjhcYlv\SC{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGsyKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC0PEBpenNiYomgX\|NJZWi7cH;4ZY51cGmwZTDpcoNwenCxcnH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4yPSEQvF2u	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2NEKxOUc,Ojd\|NESyNVU9N2F-
red blood cells	NIe0VGRCdnSrcHzhd41w\GmjbDDhd5NigQ>?		M37FVFQ5KGi{cx?=	MnG4RY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCCjc3X4eYFtKGW{eYTodo9kgXSnIIP0ZYdmKG:oIHPocI9zd3G3aX7lMZJme2m\|dHHueEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iRHSyJIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB2ODDodpMh[nlibHHjeIF1\SCmZXj5[JJw\2WwYYPlJIF{e2G7LDDJR\|UxKD1iMD6xOUDPxE1w	NGjKeVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK5OlY5Oyd-M{CyPVY3QDN:L3G+
red blood cells	MUfBcpRqdWGuYYLpZYwh[XO\|YYm=		NUe3WGZiPDhiaILz	NH7WWWZCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCvdXz0bYRzfWdvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBMOSCrbn\lZ5Rm\CCrbjDoeY1idiC{ZXSgZoxwd2RiY3XscJMh[XO\|ZYPz[YQh[XNiM1itbJlxd3ijboTobY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHzpdZVq\CC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gNE4yPyEQvF2u	M3zpWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkS0OVQyLz5{MU[0OFU1OTxxYU6=
L6	M4TpNGFvfGmyYYLhd4l1cWNiYYPzZZk>		MXu0PEBpenN?	NVnI[mRLSW62aYDhdoF{cXSrYzDhZ5Rqfmm2eTDh[4FqdnO2IGDsZZNud2SrdX2g[oFt[2myYYL1cUBMOSCrbn\lZ5Rm\CCrbjDyZZQhVDZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBx[XKjc3n0[UBoem:5dHigdJJmcW6ldXLheIVlKG[xcjC0PEBpenNiYnXmc5JmKFt\|SG3ofZBwgGGwdHjpcoUh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNlQhcHK\|IHL5JHs{UF2qeYDvfIFvfGirbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFAvOTd6IN88UU4>	Mn\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7M{eyNlgoRjJzOUO3NlI5RC:jPh?=
L6	NYC5cnNkS3m2b4TvfIlkcXS7IHHzd4F6			NUe1[FVHS3m2b4TvfIlkcXS7IHHnZYlve3RicnH0JGw3KGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5zOEi1JO69VS5?	M1jPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4NVc4Lz5zN{G3PFE4PzxxYU6=
red blood cells	NH;CS4FCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MnfzOFghcHK\|	NXnqdHY{SW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDD0bIUhdXWudHnkdpVoNXKnc3nzeIFvfCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gSnJENTNiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBx[XKjc3n0[UBoem:5dHigZYZ1\XJiNEigbJJ{KGK7IFjv[YNpe3RiM{OzOFIhe3SjaX7pcoch[mG\|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6yNFch\|ryPLh?=	NX;hZXd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxPVk4ODZpPkOwNVk6PzB4PD;hQi=>
red blood cells	NYTFNWtmSW62aX3hcIFzcWGuIHHzd4F6		MWK0PEBpenN?	MV;BcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiZYL5eIhzd2O7dHnjJJN1[WenIH;mJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCNMTDpcoZm[3SnZDDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IGuzTH0ucHmyb4jhcpRpcW6nIHnuZ49zeG:{YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlIyKM7:TT6=	M{PYRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nki1OVY6Lz5{M{[4OVU3QTxxYU6=
red blood cells	MWnBcpRqeGyjc33v[IlidCCjc4PhfS=>		M1KxSFQ5KGi{cx?=	NYrXS3VKSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[U0h[W6mIID5dolu\XSqYX3pcoUuemW\|aYP0ZY51KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDLNUBqdm[nY4Tl[EBqdiCqdX3hckBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMhYzOKXXj5dI95[W62aHnu[UBqdmOxcoDvdoF1cW:wIHHmeIVzKDR6IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNlIh\|ryPLh?=	NFHMUm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSzPFU5Pid-MkG0N\|g2QDZ:L3G+
red blood cells	MVrBcpRqdWGuYYLpZYwh[XO\|YYm=			NIrNTFlCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCC{aX7nJJN1[WenIGDsZZNud2SrdX2g[oFt[2myYYL1cUBYOiCrbn\lZ5Rm\CC5aYToJIh2dWGwIILl[EBjdG:xZDDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OCB;IECuNlI6KM7:TT6=	MoHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkW2NFgoRjJ3N{K1OlA5RC:jPh?=
L6	M1e4Z2FvfGmyYYLhd4l1cWNiYYPzZZk>			MUXBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVuIID5dolu\XSqYX3pcoUuemW\|aYP0ZY51KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDLNUBmenm2aILvZ5l1\SC\|dHHn[UBqdm[nY4Tl[EBz[XRiTE[gZ4VtdHNuIFnDOVAhRSByLkKzJO69VS5?	NVnXSXdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OFkxPjhpPkG3PVQ6ODZ6PD;hQi=>
L6	NWL2UId3SW62aYDsZZNud2SrYXygZZN{[Xl?			NITORVhCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lJIFv\CCyeYLpcYV1cGGvaX7lMZJme2m\|dHHueEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iS{GgbY5n\WO2ZXSgbY4hemG2IFy2JINmdGy\|LDDJR\|UxKD1iMD6yOUDPxE1w	NIPtdW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm0NlQ{QSd-MUm5OFI1Ozl:L3G+
red blood cells	M17I[GFvfGmvYXzhdolidCCjc4PhfS=>		MlPwO\|IhcHK\|	NX62TFMySW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCZMjDpcoZm[3SnZDDpckBpfW2jbjDBMZBwe2m2aY\lJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB5MjDodpMh[nlibHHjeIF1\SCmZXj5[JJw\2WwYYPlJIF{e2G7LDDJR\|UxKD1iMD6yOUDPxE1w	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{M{C3OEc,OjFzMkOwO\|Q9N2F-
red blood cells	MVTBcpRqdWGuYYLpZYwh[XO\|YYm=		NWPid3ZyPDhiaILz	NEH5[ZVCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSgVIxie22xZHn1cUBn[WylaYDhdpVuKE[lTUK5JIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB2ODDodpMh[nliW{PIYU1pgXCxeHHueIhqdmViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNlYh\|ryPLh?=	NUCz[GE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFA1PThpPkK4PFAxPDV6PD;hQi=>
red blood cells	NGfKd2hCdnSrbXHsZZJq[WxiYYPzZZk>		NX3lSIpQPDhiaILz	MUXBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBufWy2aXTyeYcuemW\|aYP0ZY51KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDUUVkxNUN{QjDpcoZm[3SnZDDpckBpfW2jbjDPJJBwe2m2aY\lJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuzTH0ucHmyb4jhcpRpcW6nIIXweIFs\SCjZoTldkA1QCCqcoOsJGlEPTBiPTCwMlI5KM7:TT6=	M1nFbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OVk{Lz5{MUG1OVU6OzxxYU6=
red blood cells	M{\NS2FvfGmvYXzhdolidCCjc4PhfS=>		NWezXVBUPDhiaILz	NEHyTGdCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCC{aX7nJJN1[WenIGDsZZNud2SrdX2g[oFt[2myYYL1cUBF\DJiaX7m[YN1\WRid3n0bEBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhW1mEUjDHdoVmdiCvZYToc4QtKEmFNUCgQUAxNjJ6NTFOwG0v	M3LMR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K1OlA5Lz5{NUeyOVYxQDxxYU6=
red blood cells	NIn5fnlCdnSrbXHsZZJq[WxiYYPzZZk>		MmO0PVYhcHK\|	MkLDRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmViYX7kJJB6emmvZYToZY1qdmVvcnXzbZN1[W62IHXhdox6KHS{b4Doc5pwcXSnIIP0ZYdmKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBYOiCrbjDoeY1idiC{ZXSgZoxwd2RiY3XscJMh[XO\|ZYPz[YQh[XNiW{PIYYh6eG:6YX70bIlv\SC3cIThb4Uh[W[2ZYKgPVYhcHK\|LDDJR\|UxKD1iMD6yPUDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2OEK4NUc,OjN2NEiyPFE9N2F-
red blood cells	M4TveGFvfGmvYXzhdolidCCjc4PhfS=>		NXL4VYx6PzJiaILz	MWfBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwZnXjeIVlKGmwIHj1cYFvKHS7cHWgRU1xd3OrdHn2[UBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JJNx\WO2cn;wbI91d22ndILpZ4FtdHluIFnDOVAhRSByLkOxOkDPxE1w	NHTFWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOxNVU3Oid-MkWzNVE2PjJ:L3G+
red blood cells	NFv2dlJCdnSrbXHsZZJq[WxiYYPzZZk>		Mlj1O\|IhcHK\|	MWnBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwZnXjeIVlKGmwIILl[EBjdG:xZDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVWGuc4TheEBz\WGpZX70JIJie2WmIFzETEBie3OjeTygTWM2OCB;IECuN\|E4KM7:TT6=	MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkKzNVcoRjJ6MkKyN\|E4RC:jPh?=
red blood cells	NV:weot1SW62aYDsZZNud2SrYXygZZN{[Xl?		MVe3NkBpenN?	M{PYeGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCZMjDpcoZm[3SnZDDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHCjcnHzbZRmKGyjY4TheIUh\GWqeXTyc4dmdmG\|ZTDhd5NigSxiSVO1NEA:KDBwM{G3NUDPxE1w	NWnje2JSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NVc5PTdpPkKyPVE4QDV5PD;hQi=>
red blood cells	NH;Yd4dCdnSrcHzhd41w\GmjbDDhd5NigQ>?		NI\5N\|g4OiCqcoO=	NXHyXVVRSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[U1z\XOrc4ThcpQhWGyjc33v[Il2dSCoYXzjbZBienWvIGeyJIlv\mWldHXkJIlvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC3NkBpenNiYomgdIFz[XOrdHnjJGxFUCCjc4PhfUwhUUN3MDC9JFAvOzlizszNMi=>	Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC1NFkoRjJ2OUCwOVA6RC:jPh?=
red blood cells	NH3LNnZCdnSrbXHsZZJq[WxiYYPzZZk>		MlKyOFghcHK\|	NXjiXFFlSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWgZY5lKHC7cnnt[ZRp[W2rbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCNMTDpcoZm[3SnZDDpckBpfW2jbjDPJJBwe2m2aY\lJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuzTH0ucHmyb4jhcpRpcW6nIIXweIFs\SCjZoTldkA1QCCqcoOsJGlEPTBiPTCwMlQh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NUW5N{c,OjFzNUW1PVM9N2F-
red blood cells	M2\1fmFvfGmvYXzhdolidCCjc4PhfS=>			MUnBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gdIFz[XOrdHnjJGxFUCCjY4Tpeol1gSCkeTDNZYx{fGG2IILlZYdmdnRiYnHz[YQhe3CnY4Tyc5Bpd3SxbXX0dolkKG2ndHjv[EwhUUN3MDC9JFAvPDJizszNMi=>	NHqzd4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiwNFQ2QCd-Mki4NFA1PTh:L3G+
red blood cells	M3LXTmFvfGmybHHzcY9lcWGuIHHzd4F6		Mn\qO\|IhcHK\|	M4DleWFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCZMjDpcoZm[3SnZDDpckBz\WRiYnzvc4Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3hcJN1[XRicnXh[4VvfCCkYYPl[EBNTEhiYYPzZZktKEmFNUCgQUAxNjR\|IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5PEc,Ojh\|MUW1PVg9N2F-
Vero	NUHwUoVlSW62aX3hcIFzcWGuIHHzd4F6		MmjZO\|IhcHK\|	NF35XGRCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSgVIxie22xZHn1cUBn[WylaYDhdpVuKFd{IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KCiFZYLjc5BqfGinY4XzJIFmfGirb4DzLUApS2W{Y3;wbZRp\WO3czDh[ZRpcW:yczmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCyYYLhd4l1\SCORFigZYN1cX[rdImgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC52OESg{txONg>?	NITLWoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUizN\|UzOCd-MUm4N\|M2OjB:L3G+
HEK293	NILFT3FEgXSxdH;4bYNqfHliYYPzZZk>		NIXKeow4OiCqcoO=	MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCmeXWgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjR7IN88UU4>	NXTyV3JXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyN\|Y1QTJpPkK5NlM3PDl{PD;hQi=>
red blood cells	MW\BcpRqdWGuYYLpZYwh[XO\|YYm=		MYW3NkBpenN?	MVHBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwZnXjeIVlKGmwIHj1cYFvKHS7cHWgRU1xd3OrdHn2[UBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMheGG{YYPpeIUhdGGldHH0[UBl\Wi7ZILv[4Vv[XOnIHHjeIl3cXS7IHHmeIVzKDd{IHjyd{BjgSC\|cHXjeJJweGixdH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkWyJO69VS5?	NIHJfmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC1OFA{QCd-MkKwOVQxOzh:L3G+
red blood cells	MX\BcpRqeGyjc33v[IlidCCjc4PhfS=>		M{DVS\|Q5KGi{cx?=	MonlRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSgVIxie22xZHn1cUBn[WylaYDhdpVuKFd{IHnu[oVkfGWmIHnuJIh2dWGwIILl[EBjdG:xZDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1mEUjD0[ZN1NCCLQ{WwJF0hOC53OTFOwG0v	MlqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEizNFMoRjJ4OUi4N\|A{RC:jPh?=
red blood cells	MVrBcpRqdWGuYYLpZYwh[XO\|YYm=		MXy0PEBpenN?	NGPOPJJCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCvdXz0bYRzfWdvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBVVTl\|LVOxNFg5KGmwZnXjeIVlKGmwIHj1cYFvKE9icH;zbZRqfmVicnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhYzOKXT3ofZBwgGGwdHjpcoUhfXC2YXvlJIFnfGW{IES4JIhzeyxiSVO1NEA:KDBwNkKg{txONg>?	M{PSUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OVk{Lz5{MUG1OVU6OzxxYU6=
Dd2	MlzSRY51cXCuYYPtc4Rq[WxiYYPzZZk>			MmfCRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCCmcoXnJJJme2m\|dHHueEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iRHSyJJJqdmdic4Th[4Uh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKHCjcnHzbZRmdWmjIHL5JG1idHO2YYSgZZN{[XluIFnDOVAhRSByLkexJO69VS5?	NGHBOHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1PFMxOCd-MkK4OVg{ODB:L3G+
red blood cells	NEGwSY1CdnSrbXHsZZJq[WxiYYPzZZk>		NF;QZY04OiCqcoO=	NEfnXJJCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSgVIxie22xZHn1cUBn[WylaYDhdpVuKFd{IHnu[oVkfGWmIHnuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB5MjDodpMh[nliU2nCVkBoemWnbjCxJJN1[WmwaX7nJIJie2WmIH\seY9zd22ndILpZ{Bie3OjeTygTWM2OCB;IECuO\|Uh\|ryPLh?=	NYfMeI5vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2PVI5OzFpPkK3OlkzQDNzPD;hQi=>
red blood cells	NXqwWFVLSW62aX3hcIFzcWGuIHHzd4F6		M3ixTFQ5KGi{cx?=	MVjBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\SxicInybY1mfGijbXnu[Uwh[W6mIH3l[oxweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGZEKgbY5n\WO2ZXSgbY4hcHWvYX6gU{Bxd3OrdHn2[UBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN2heNWi7cH;4ZY51cGmwZTD1dJRic2ViYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE46QCEQvF2u	NFK3Opo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
HepG2	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=		MoPmO\|IhcHK\|	MoSyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh\XiycnXzd4lv\yCFREixJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKt[4xwKGG\|c3H5MEBESzVyIE2gNU43KM7:TT6=	NFqxRm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NVY4PSd-MkW3PVE3PzV:L3G+
HepG2	NWS3fWk6SW62aYDsZZNud2SrYXygZZN{[Xl?		M3PxWVQ5KGi{cx?=	MXnBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KGyrdnXyJJN1[WenIH;mJHBt[XOvb3TpeY0hgW:nbHnpJFE4YCCQTDDzdI9zd3qxaYTld{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\XCJMjDj[YxteyCneIDy[ZN{cW6pIFPEPFEh[W[2ZYKgOFghcHK\|IHL5JGRCWElic4ThbY5qdmdvYnHz[YQhcW2vdX7v[ox2d3Knc3PlcoNmKGGwYXz5d4l{NCCLQ{WwJF0hOS54NTFOwG0v	MnPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUG2O\|UoRjJ3N{mxOlc2RC:jPh?=
WI38	MYjBcpRqfmm{YXygZZN{[Xl?		M4rQeVIhcHK\|	NVfCZ3NjSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhSkuYIFfhdoRv\XJiQWTDR{BXWjh\|NzDpcoZm[3SnZDDpckBpfW2jbjDXTVM5KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJidCCGTlGgcIV3\WxicILlbY5kfWKjdHXkJIZweiB{IHjyd{Bj\W[xcnWgeolz[WxiaX7m[YN1cW:wIH3lZZN2emWmIHHmeIVzKDdiZHH5d{BjgSC{ZXHsJJRqdWViUFPSJIF{e2G7LDDFR\|UxKD1iMT63JO69VS5?	MnXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd6OUOxOVgoRjF5OEmzNVU5RC:jPh?=
HeLa	NFTPeIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXix[IxYPDhiaILz	MknLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGwNEB2VSCcblPsNkwhT0l3MDC9JFIvOSEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEe4Okc,OTl5NEi3PFY9N2F-
SMB	NV7SWWl5SW62aYDybY9vKGG\|c3H5			MlvRRY51cXC{aX;uJIFkfGm4aYT5JIFo[Wmwc4SgR4hidmSuZYKgd5Rz[WmwIH;mJJNp\WWyIIPjdoFxcWVicILpc44heHKxdHXpckBqdm[nY4Tl[EBqdiCvb4Xz[UBUVUJiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZJidmOnIH;mJIRqe2Wjc3WtZZN{d2OrYYTl[EB{[3KjcHnlJJBzcW:wIIDyc5RmcW5uIFXDOVAhRSB{LkOg{txONg>?	NY\GZZJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O\|A5OzdpPkKxOVcxQDN5PD;hQi=>
HEK293	M4rMcGZ2dmO2aX;uJIF{e2G7			NYH5c5gxUW6qaXLpeIlwdiCxZjDoeY1idiCHUleg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idHHpcEBkfXK{ZX70JIF1KG2nbXLyZY5mKHCxdHXueIlidCCxZjCrNlAhdVZuIFnDOVAhRSB{LkWg{txONg>?	NUTnXXJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFY5OTZpPkK1O\|Q3QDF4PD;hQi=>
red blood cells	NXy1NZlGSW62aX3hcIFzcWGuIHHzd4F6		NGey[oczPCCqcoO=	NELzbpdCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKDOGNzDpcoZm[3SnZDDpckBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIH3heJVz\SC\|Y3jpfo9vfHNiZn;ycYF1cW:wIHHmeIVzKDJ2IHjyd{BjgSCJaXXtd4Eue3SjaX7pcoch[mG\|ZXSgZZN{[XluIFXDOVAhRSB{Lkm3JO69VS5?	NGjKfZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS5PVQ5Pid-Mkm0PVk1QDZ:L3G+
HEK293	NX74eJlqTnWwY4Tpc44h[XO\|YYm=			M2PrOYhGWkdiYnnu[Ilv\yCjc4PhfZM7KESrc4DsZYNmdWWwdDDv[kBcO0ifLVTv[oV1cWyrZHWgLFUhdk1iZnnuZYwqKG[{b32gbGVTTyCvZX3idoFv\XNib3L0ZYlv\WRiZoLvcUBJTUt{OUOgZ4VtdHNuIFvpJF0hOy5zNkKyPEDPxE1w	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjN3M{i1PUc,OzJ\|NUO4OVk9N2F-
1205 Lu	NUT1RZA6S3m2b4TvfIlkcXS7IHHzd4F6		M{frSVczKGi{cx?=	MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxNlA2KEy3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA{NjZizszNMi=>	M1ewZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm5NVU4Lz5{NU[5PVE2PzxxYU6=
LN229	NIP3WopEgXSxdH;4bYNqfHliYYPzZZk>		NGPUfVg4OiCqcoO=	MofGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG4zOjliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFMvPiEQvF2u	NYDueoQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVkyPTdpPkK1Olk6OTV5PD;hQi=>
C8161	NFj1OplEgXSxdH;4bYNqfHliYYPzZZk>		Mmj0O\|IhcHK\|	NEjr[29EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEQDF4MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy54IN88UU4>	NVvFOHVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVkyPTdpPkK1Olk6OTV5PD;hQi=>
HT-29	Mn;kR5l1d3SxeHnjbZR6KGG\|c3H5		NXrle49jPzJiaILz	M{HvfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA{NjZizszNMi=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7OUG1O{c,OjV4OUmxOVc9N2F-
WI38	NFO2NW9EgXSxdH;4bYNqfHliYYPzZZk>		MWeyOEBpenN?	M2rBS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHdKOzhiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxem:uaX\ldoF1cW:wIHHmeIVzKDJ2IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB\|Lk[zJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4MUOwPUc,OjV2NkGzNFk9N2F-
ScN2a	MYnGeY5kfGmxbjDhd5NigQ>?			NGjDd4NJ[WyoIH3hfIlu[WxiaX7obYJqfGmxbjDv[kBRemmxbjDwdo91\WmwIGDyVJNkKG[xcn3heIlwdiC5YYOgZZN{[XmnZDDpckBU[05{YTDj[YxteyxiRVO1NEA:KDRizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjlyNEC1PUc,OTJ7MESwOVk9N2F-
HepG2	M2C2SGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4jrOFI1KGi{cx?=	MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjCyOEBpenNiYomgcoV2fHKjbDDy[YQh\HmnIIXweIFs\SCjc4PhfUwhXEN3MDC9JFQvOyEQvF2u	M3POe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{izPVg1Lz5{Mke4N\|k5PDxxYU6=
HeLa	NV\zZY9GT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mk[1OFghcHK\|	M1eyN2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUBqdiCycnXz[Y5k\SCxZjC1NEB2VSCFdVPsNkwhT0l3MDC9JFQvPCEQvF2u	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEe4Okc,OTl5NEi3PFY9N2F-
HeLa	NWrFOWhiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NI\TRng1QCCqcoO=	M{Poemdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNEB2VSCFdVPsNkwhT0l3MDC9JFUvOyEQvF2u	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEe4Okc,OTl5NEi3PFY9N2F-
HeLa	NEDCdldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHHMdYc1QCCqcoO=	MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiNUCgeW0hYm6FbEKsJGdKPTBiPTC1MlYh\|ryPLh?=	M4facFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|g3Lz5zOUe0PFc5PjxxYU6=
HeLa	NXS0TmNmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX;NZ\|FxPDhiaILz	M{WwZWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxJJVOKEO3Q3yyMEBIUTVyIE2gOk4yKM7:TT6=	NX7pNYhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFg4QDZpPkG5O\|Q5Pzh4PD;hQi=>
SH-SY5Y	NWraOHFDTnWwY4Tpc44h[XO\|YYm=		M3LCWFI1KGi{cx?=	NX7SOoxnVW:mdXzheIlwdiCxZjDoeY1idiC5aXzkMZR6eGViQWDQOlk2KGW6cILld5Nm\CCrbjDTTE1UYTW\IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[W27bH;p[EBj\XSjIDixJJRwKDRyIILld4llfWW\|KTDwdo9lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyxiSVO1NEA:KDdizszNMi=>	M1nUb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUW5NVk5Lz5{OUW1PVE6QDxxYU6=
SH-SY5Y	NV22OZluTnWwY4Tpc44h[XO\|YYm=		MXOyOEBpenN?	MXPJcohq[mm2aX;uJI9nKEKDQ1WxJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDBVHA3QTViYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGGveXzvbYQh[mW2YTCoNUB1dyB2MDmgcIV3\WxiYX\0[ZIhOjRiaILzJIJ6KEWOSWPBJI1mfGixZDygTWM2OCB;IEeg{txONg>?	NInwNG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK2PFgzOid-M{CyOlg5OjJ:L3G+
CHO	NVLHb5ZpTnWwY4Tpc44h[XO\|YYm=			M2DZdWlvcGmkaYTpc44hd2ZiaIXtZY4hTVKJIHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEurIE2gO{42KM7:TT6=	NGr2UGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFYxOyd-MkS5NFA3ODN:L3G+
L6	NEnOdGxEgXSxdH;4bYNqfHliYYPzZZk>			MlzwR5l1d3SxeHnjbZR6KGGpYXnud5QhVDZiY3XscJMtKEmFNUCgQUA4NjdizszNMi=>	NGr4bFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K4NFg{PSd-MUeyPFA5OzV:L3G+
HepG2	Mnf5R5l1d3SxeHnjbZR6KGG\|c3H5		NWGyTHJGPzJiaILz	NFjKfmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA5NjNizszNMi=>	Ml;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW1PVMoRjJzMUW1OVk{RC:jPh?=
WI38	MV7DfZRwfG:6aXPpeJkh[XO\|YYm=		NVGwRWt7OiCqcoO=	NULSNJdVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hX0l\|ODDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubIXsZZIhTE6DIHzleoVtKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOgZoVnd3KnII\pdoFtKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA4KGSjeYOgZpkhemWjbDD0bY1mKFCFUjDhd5NigSxiQ1O1NEA:KDhwNTFOwG0v	M1LXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OEmzNVU5Lz5zN{i5N\|E2QDxxYU6=
HepG2	NHn2Z5FCdnSrbXHsZZJq[WxiYYPzZZk>			MoTmRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qhe3Cxcn;6c4l1\SC\|dHHn[UBw\iCSbHHzcY9lcXWvIHLldodp\WlieX;lcIlqKGmwZnXjeIVlKGmwIHj1cYFvKEincFeyJINmdGy\|LDDJR\|UxKD1iOTFOwG0v	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NEC5PFEoRjJ4NkSwPVgyRC:jPh?=
SKHep	M2Ph[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2Ds[FQ5KGi{cx?=	MVnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT2hmeCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGwKUBHSlNic4XwdIxmdWWwdHXkJGROTU1ibXXkbZVuNCCJSUWwJF0hQS53IN88UU4>	NI\1Ro09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFc5Pid-MUm3OFg4QDZ:L3G+
HeLa	NGjOWnlEgXSxdH;4bYNqfHliYYPzZZk>		NYXmO4V4PyCqcoO=	M1zhdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB{fXK4aY\hcEBi\nSncjC3JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC5MlY3PSEQvF2u	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzd4OEC1Nkc,OTd5NkiwOVI9N2F-
HeLa	M{jtSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2HyPFch\GG7cx?=	MoLmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC3JIRigXNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gPU43PyEQvF2u	MoPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2OEm3PFkoRjJzNEi5O\|g6RC:jPh?=
K562	M1y5[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYqyOEBpenN?	MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIF{e2W\|c3XkJIF{KHKjZHnvZYN1cX[nIITofY1q\GmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFI1KGi{czygR2M2OCB;IEmuO{DPxE1w	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ6MEK3PEc,OTh4OECyO\|g9N2F-
Vero	MWnBcpRqfmm{YXygZZN{[Xl?		Mmq1OkB1dyB5IHThfZM>	NXfweXpkSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qh[2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJI9k\WGwIIP0doFqdiB6OUmgbY5n\WO2ZXSgbY4hXmW{bzDj[YxteyCjc4Pld5Nm\CCjczD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGGodHXyJFYhfG9iNzDkZZl{NCCHQ{WwJF0hOTBizszNMi=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl5MEW2NUc,OjV7N{C1OlE9N2F-
PDAC	NHzwZWpHfW6ldHnvckBie3OjeR?=			NFK1Z3VKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDv[kBRTEGFIHPlcIx{KCi3bnvuc5dvKG:{aXfpckktKEmFNUCgQUAyOCEQvF2u	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|NUS3NUc,OjZzM{W0O\|E9N2F-
Vero	MmHhRY51cX[rcnHsJIF{e2G7		M{KzdVYhfG9iNzDkZZl{	NUewfHhPSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhQDl7IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJINmdGxiZHXheIgh[W[2ZYKgOkB1dyB5IHThfZMh[nliTWTTJIF{e2G7LDDFR\|UxKD1iMUCg{txONg>?	M3L0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUK2PFA4Lz5{NEmyOlgxPzxxYU6=
HepG2	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		MUi0PEBpenN?	NHXNeXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA1QCCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiRVO1NEA:KDFyLkGg{txONg>?	M1XxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OECwPFI4Lz5{OUiwNFgzPzxxYU6=
BT-483	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkfkOFghcHK\|	MnvLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRnQuPDh\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhcW5icILld4Vv[2Vib3[gNVAmKE[EUzDzeZBxdGWvZX70[YQhTE2HTTDt[YRqfW1uIFfJOVAhRSBzMD6yJO69VS5?	NV7vXlRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFg4QDZpPkG5O\|Q5Pzh4PD;hQi=>
Vero	NE\QSYFCdnSrdnnyZYwh[XO\|YYm=		MUG1JIRigXN?	MUnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDDbIlsfW6pdX75ZUB3cXK3czDJcoRq[W5iT3PlZY4hQDh7IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIFnfGW{IEWg[IF6eyCkeTDNWHMwWE2VIH3leIhw\CxiRVO1NEA:KDFzIN88UU4>	MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|M{[5OVEoRjJ7M{O2PVUyRC:jPh?=
Vero A	NVLvTplPSW62aY\pdoFtKGG\|c3H5		NF;QVVg3KHSxIEeg[IF6ew>?	M2T1eGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGNpcWu3bnf1cpliKH[rcoXzJGlv\GmjbjDvZ4VidiC\|dILhbY4hQDl7IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gRUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idnnyZYwucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBi\nSncjC2JJRwKDdiZHH5d{BjgSCPVGOvVG1UKGG\|c3H5MEBGSzVyIE2gNVEh\|ryPLh?=	NWnFNm46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2O\|E5OzJpPkK4OlcyQDN{PD;hQi=>
Vero	NHToRZlCdnSrdnnyZYwh[XO\|YYm=		NXnBUJkyPSCmYYnz	NU[0fpJ2SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJG9k\WGwIIP0doFqdiB6OUmgbY5n\WO2ZXSgbY4hSW[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtNWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5QhdWWjc4Xy[YQhd25iZHH5JFUheG:\|dDDpcoZm[3Srb36gZpkhVVSVL2DNV{Bie3OjeTygSWM2OCB;IEGxJO69VS5?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4O{c,Ojl2OUm0PFc9N2F-
Vero	MmP3RY51cX[rcnHsJIF{e2G7		MkPXO{Bl[Xm\|	NWnGPHNVSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJG9k\WGwIIP0doFqdiB6OUmgbY5n\WO2ZXSgbY4hSW[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[W[2ZYKgO{Bl[Xm\|IHL5JG1VWy:STWOgcYV1cG:mLDDFR\|UxKD1iMUGg{txONg>?	NELucZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwNFYzPid-MkS4NFA3OjZ:L3G+
Vero	MUnBcpRqfmm{YXygZZN{[Xl?		MX23JIRigXN?	NF[yVGVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBUcW6mYnnzJJZqenW\|IIP0doFqdiCKUoPwJIlv\mWldHXkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IG\ldo8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2eyCrbnT1Z4VlKGOnbHyg[IVifGhibXXhd5Vz\WRiYX\0[ZIhPyCmYYnzMEBGSzVyIE2gNVEh\|ryPLh?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NkGxOkc,OjV7NE[xNVY9N2F-
Vero	NXfWV5kzSW62aY\pdoFtKGG\|c3H5		MYC3JIRigXN?	MX7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDDbIlsfW6pdX75ZUB3cXK3czDzeJJicW5iOEm5JIlv\mWldHXkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IG\ldo8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2eyCrbnT1Z4VlKGOnbHyg[IVifGhibXXhd5Vz\WRiYX\0[ZIhPyCmYYnzMEBGSzVyIE2gNVEh\|ryPLh?=	NFrwXoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OlEyPid-MkW5OFYyOTZ:L3G+
Vero	NW\jfJUzSW62aY\pdoFtKGG\|c3H5		MlvlOkB1dyB5IHThfZM>	M{XvXmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHNqdmSkaYOgeolzfXNiSGLzdEBqdm[nY4Tl[EBqdiCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CClZXzsJIRm[XSqIHHmeIVzKDZidH:gO{Bl[Xm\|IHL5JG1VWyCjc4PhfUwhTUN3MDC9JFEyKM7:TT6=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{NkiwO{c,OjR7Mk[4NFc9N2F-
Vero	MYnBcpRqfmm{YXygZZN{[Xl?		NH3lbVY3KHSxIEeg[IF6ew>?	NYCxdJBESW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhW2mwZHLpd{B3cXK3czDIVpNxKGmwZnXjeIVlKGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHnuZ5Vj[XSnZDDmc5IhPiC2bzC3JIRigXNiYomgUXRUKGG\|c3H5MEBGSzVyIE2gNVEh\|ryPLh?=	MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{MUW0OlAoRjJ\|MkG1OFYxRC:jPh?=
Vero	M2PKWmFvfGm4aYLhcEBie3OjeR?=		NFvLUGs3KHSxIEeg[IF6ew>?	M{f0bWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGNpcWu3bnf1cpliKH[rcoXzJFg6QSCrbn\lZ5Rm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDpcoN2[mG2ZXSg[o9zKDZidH:gO{Bl[Xm\|IHL5JG1VWyCjc4PhfUwhTUN3MDC9JFEyKM7:TT6=	M1i4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1OFYxLz5{M{KxOVQ3ODxxYU6=
red blood cells	M3j0UGFvfGmvYXzhdolidCCjc4PhfS=>		NUWwSYZ7PDhiaILz	Ml;RRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBMOTRiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGGodHXyJFQ5KGi{czDifUBcO0ifaInwc5hidnSqaX7lJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUCgQUAyOSEQvF2u	NEfSW5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK4NlI3OCd-MkWyPFIzPjB:L3G+
red blood cells	MUfBcpRqdWGuYYLpZYwh[XO\|YYm=		MX[yOEBpenN?	MWfBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHJMVDliaX7m[YN1\WRiaX6gdoVlKGKub3;kJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCvYYT1doUhe2OqaYrvcpR{KG[xcn3heIlwdiCjZoTldkAzPCCqcoOgZpkhT2mnbYPhMZN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{WwJF0hOTFwMkWg{txONg>?	NXHROlUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDZpPkK5OFk6PDh4PD;hQi=>
MCF7	NIXqcGxEgXSxdH;4bYNqfHliYYPzZZk>			M2Tr[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiW{PIYYh6eG:6YX70bIlv\SCrbnPvdpBwemG2aX;uMEBKSzVyIE2gNVIh\|ryPLh?=	MmPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MUK5PFcoRjF6NUGyPVg4RC:jPh?=
HEK293	M1jFSmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MknKO\|IhcHK\|	M4PhZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhGUzJ7MzDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAyOiEQvF2u	M2XrPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OVk{Lz5{MUG1OVU6OzxxYU6=
Vero	MWnBcpRqfmm{YXygZZN{[Xl?		M4HzNFI1KGi{cx?=	MU\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDabYtiKH[rcoXzJIlv\mWldHXkJIlvKEGocnnjZY4h\3KnZX6gcY9vc2W7IG\ldo8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCCUTlGgdoVxdGmlYYTpc44h[W[2ZYKgNlQhcHK\|IHL5JHJVNVCFUjDt[ZRpd2RuIFXDOVAhRSBzMjFOwG0v	NF\peYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC2PFYxPCd-MkiwOlg3ODR:L3G+
Vero	MoHNRY51cX[rcnHsJIF{e2G7		NH35OpIzPCCqcoO=	NW\WOnV7SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhYmmtYTD2bZJ2eyCrbn\lZ5Rm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygVm5CKHKncHzpZ4F1cW:wIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3IhdWW2aH;kMEBGSzVyIE2gNVIh\|ryPLh?=	M1fE[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEmyPFU6Lz5{OEC5Nlg2QTxxYU6=
HeLa	MXzBcpRqfmm{YXygZZN{[Xl?		NXXjO2xrPDhiaILz	NUflfogySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYMTDs[Y51cX[rcnHsJJBienSrY3zld{Bqdm[nY4Tl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JJNx\WO2cn;mcJVwem:vZYTyfUwhUUN3MDC9JFEzNjR6IN88UU4>	NX3uTo02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVg{ODBpPkKyPFU5OzByPD;hQi=>
SH-SY5Y	M2DXW2Z2dmO2aX;uJIF{e2G7		NHrEWnMzPCCqcoO=	MXzJcohq[mm2aX;uJI9nKEKDQ1WxJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDBVHA3QTViYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGGveXzvbYQh[mW2YTCoNUB1dyB2MjmgcIV3\WxiYX\0[ZIhOjRiaILzJIJ6KEWOSWPBJI1mfGixZDygTWM2OCB;IEGyMlch\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ4OEiyNkc,OzB{Nki4NlI9N2F-
SH-SY5Y	M2DFRmZ2dmO2aX;uJIF{e2G7		NWfLfodjOjRiaILz	Mm\4UY9lfWyjdHnvckBw\iCqdX3hckB4cWymLYT5dIUhSVCSNkm1JIV5eHKnc4Pl[EBqdiCVSD3TXVV[KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZY16dG:rZDDi[ZRiKChzIITvJFQzKHKnc3nkeYV{MSCycn;keYN1cW:wIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3MDC9JFEzNjhizszNMi=>	M3LqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUW5NVk5Lz5{OUW1PVE6QDxxYU6=
HepG2	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		MoL3O\|IhcHK\|	M3jrRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBCdGGvYYKgRox2\SCjc4PhfUwhUUN3MDC9JFEzNjlizszNMi=>	NUjKV45vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxPVA5PTdpPkKxNVkxQDV5PD;hQi=>
Vero	M{nDXWFvfGm4aYLhcEBie3OjeR?=		M{fHelYhfG9iNzDkZZl{	NFLMV2lCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBU\W2uaXvpJIZwemW\|dDD2bZJ2eyCYaXX0coFuKGmwZnXjeIVlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHPlcIwh\GWjdHigZYZ1\XJiNjD0c{A4KGSjeYOgZpkhVVSVIHHzd4F6NCCHQ{WwJF0hOTNwODFOwG0v	NF\qeVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyOlgxPyd-MkS5NlY5ODd:L3G+
Vero	Mk\WRY51cX[rcnHsJIF{e2G7		M2rYclch\GG7cx?=	M4nzV2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHNmdWyra3mg[o9z\XO2II\pdpV{KHO2cnHpckBXcWW2bnHtJIlv\mWldHXkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IG\ldo8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2eyCrbnT1Z4VlKGOnbHyg[IVifGhibXXhd5Vz\WRiYX\0[ZIhPyCmYYnzMEBGSzVyIE2gNVQh\|ryPLh?=	NUDO[3NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFYyOTZpPkK1PVQ3OTF4PD;hQi=>
Vero	NICxVmtCdnSrdnnyZYwh[XO\|YYm=		MXu2JJRwKDdiZHH5dy=>	MnfSRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgV4VudGmtaTDmc5Jme3RidnnyeZMhcW6oZXP0[YQhcW5iYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiaX7jeYJifGWmIH\vdkA3KHSxIEeg[IF6eyCkeTDNWHMh[XO\|YYmsJGVEPTBiPTCxOEDPxE1w	NVLuTos2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU1PjBpPkKzNlE2PDZyPD;hQi=>
NSO	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=			NXnpfHF3S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVlORIHPlcIx{KGK7IF3UWEBie3OjeTygWGM2OCB;IEG0Mlkh\|ryPLh?=	NWPpN\|NPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVM6PTVpPkG5NVE{QTV3PD;hQi=>
L1210	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=			Ml7JR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[nliQ3;1cJRmeiClb4XueIVzKGGwYXz5d4l{NCCLQ{WwJF0hOTVizszNMi=>	NVfEPFF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVQ5OTFpPkK2NVE1QDFzPD;hQi=>
Huh-7	NV\0bVJiSW62aYDsZZNud2SrYXygZZN{[Xl?		MVW0PEBpenN?	MUPBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iYnXy[4hmcSCuaY\ldkB{fGGpZTDmc5JuKHS{YX7z[oVkfGWmIHnuJIh2dWGwIFj1bE04KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAyPS57IN88UU4>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ5M{CzPEc,OjN{N{OwN\|g9N2F-
Daudi	NHjVU4REgXSxdH;4bYNqfHliYYPzZZk>			MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEZZVlcSClZXzsd{BjgSCPVGSgZZN{[XluIGTDOVAhRSBzNj63JO69VS5?	NYfQfGp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVM6PTVpPkG5NVE{QTV3PD;hQi=>
HeLa	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=			M2HrdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[nliQ3;1cJRmeiClb4XueIVzKGGwYXz5d4l{NCCLQ{WwJF0hOThizszNMi=>	MoO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUS4NVEoRjJ4MUG0PFEyRC:jPh?=
J774.1	MmPDR5l1d3SxeHnjbZR6KGG\|c3H5		MknRNlQhcHK\|	NYjqRnZKS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhUjd5ND6xJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCDbHHtZZJDdHWnIHLhd4VlKGO7dH;0c5hq[2m2eTDhd5NigSxiSVO1NEA:KDF6LkSg{txONg>?	M{DMO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{G2OVQzLz5{N{OxOlU1OjxxYU6=
HeLa	MnqwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFvOXWI1QCCqcoO=	NWrpPY42T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJFExLSCIQmOgd5VxeGynbXXueIVlKESPRV2gcYVlcXWvLDDHTVUxKD1iMUiuOkDPxE1w	M{nFXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|g3Lz5zOUe0PFc5PjxxYU6=
MCF7	NFH0S\|JEgXSxdH;4bYNqfHliYYPzZZk>		NU\hTGtRPDhiaILz	MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGNEPTBiPTCxPU41KM7:TT6=	NWXudFFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwNVQ5PTdpPkKwNFE1QDV5PD;hQi=>
MCF7	NYnpfm1IS3m2b4TvfIlkcXS7IHHzd4F6		M1fQRVQ5KGi{cx?=	MlrpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKHKnZIXjeIlwdiCjc4PhfUwhS0N3MDC9JFE6NjRizszNMi=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6NkCxN{c,OjR4OE[wNVM9N2F-
MCF7	NEDZdGlEgXSxdH;4bYNqfHliYYPzZZk>		M4nuXlQ5KGi{cx?=	M{HwZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiQ1O1NEA:KDF7LkSg{txONg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NEWyOEc,OjR3OUS1NlQ9N2F-
MDA-MB-468	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4PjNFczKGi{cx?=	NECwbmFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDF7Lki2JO69VS5?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZyMkiyO{c,OjZ4MEK4Nlc9N2F-
KB	Mni4R5l1d3SxeHnjbZR6KGG\|c3H5		M4\5SVQ5KGi{cx?=	M3PBTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyNE41KM7:TT6=	MmnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6MEmwO\|UoRjFzOEC5NFc2RC:jPh?=
Vero	M2X4e2FvfGm4aYLhcEBie3OjeR?=		NF:3W5A2KGSjeYO=	MWLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDDbIlsfW6pdX75ZUB3cXK3czDJcoRq[W5iT3PlZY4hQDh7IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIFnfGW{IEWg[IF6eyCkeTDNWHMwWE2VIH3leIhw\CxiRVO5NEA:KDJzIN88UU4>	NGPMOZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOzOlk2OSd-MkmzN\|Y6PTF:L3G+
Vero	NV25[oQxSW62aY\pdoFtKGG\|c3H5			NG\ZWnRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBEcGmtdX7neY56[SC4aYL1d{BKdmSrYX6gU4Nm[W5ic4TyZYlvKDh7OTDpcoZm[3SnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBu\WG\|dYLl[EBwdiCmYYmgOUBxd3O2IHnu[oVkfGmxbjDifUBOXFNxUF3TJIF{e2G7LDDFR\|kxKD1iMkGg{txONg>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4O{c,Ojl2OUm0PFc9N2F-
Vero	M3j1e2FvfGm4aYLhcEBie3OjeR?=		NVLuRmE2PyCmYYnz	NHrTRoFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBEcGmtdX7neY56[SC4aYL1d{BKdmSrYX6gU4Nm[W5ic4TyZYlvKDh7OTDpcoZm[3SnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBi\nSncjC3JIRigXNiYomgUXRUN1CPUzDt[ZRpd2RuIFXDPVAhRSB{MTFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyME[yOkc,OjR6MEC2NlY9N2F-
Vero	MmPQR5l1d3SxeHnjbZR6KGG\|c3H5		MlfRO\|IhcHK\|	M{jscmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGGocnnjZY4h\3KnZX6gcY9vc2W7IG\ldo8h[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIyKM7:TT6=	MnzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mke1N\|goRjJ\|N{K3OVM5RC:jPh?=
HepG2	NGH5SoREgXSxdH;4bYNqfHliYYPzZZk>		M3rEWVQ5KGi{cx?=	MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgcIFkfGG2ZTDk[Yh6\HKxZ3XuZZNmKGG\|c3H5MEBIUTVyIE2gNlIvOTZizszNMi=>	MoTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OEK4N\|EoRjJzOEiyPFMyRC:jPh?=
KB	MnHqR5l1d3SxeHnjbZR6KGG\|c3H5		NY[zdnR7PzJiaILz	NVfvN3BLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIzNjVizszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh5OUG1NEc,OTl6N{mxOVA9N2F-
MDA-MB-231	MlfyR5l1d3SxeHnjbZR6KGG\|c3H5		MVe0PEBpenN?	M2XRfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IEKyMlUzKM7:TT6=	NHWzO\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOFk4QSd-MUm4NFQ6Pzl:L3G+
MDA-MB-231	M2\YTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3mye\|Q5KGi{cx?=	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKHB3MzygdHJDKG23dHHueEBidmRiZYP0do9o\W5icnXj[ZB1d3JiZHXmbYNq\W62IF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDJ{LkWyJO69VS5?	MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NkG3NlAoRjJyNU[xO\|IxRC:jPh?=
MDA-MB-231	NIWzW\|lEgXSxdH;4bYNqfHliYYPzZZk>		Mnu1OFghcHK\|	NIHPTopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAzOi53MjFOwG0v	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexOkc,Ojh3OE[3NVY9N2F-
CEM	NETSVlZEgXSxdH;4bYNqfHliYYPzZZk>			NXvWd3Z7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGK7IFPveYx1\XJiY3;1cpRmeiCjbnHsfZNqeyxiSVO1NEA:KDJ\|IN88UU4>	MoXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUS4NVEoRjJ4MUG0PFEyRC:jPh?=
CE81T	NHrkdm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoDOOFghcHK\|	NWTzeIM2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS0V6MWSgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSCrbjDwdoV{\W6lZTDv[kAyOCViRlLTJJN2eHCuZX3lcpRm\CCGTVXNJI1m\Gm3bTygS2k2OCB;IEKzMlQh\|ryPLh?=	NXPrS49sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFg4QDZpPkG5O\|Q5Pzh4PD;hQi=>
MCF7	NIjVcXpEgXSxdH;4bYNqfHliYYPzZZk>		MUC3NkBpenN?	NV;BSINTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDueY1j\XJiaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCyN{41OyEQvF2u	NW[wcGNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|U1PzFpPkK2NVM2PDdzPD;hQi=>
HepG2	NEjpOodEgXSxdH;4bYNqfHliYYPzZZk>		M1i3TlczKGi{cx?=	NVrhdG4xS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgbY51emGlZXzseYxieiCDVGCgcIV3\WxiYX\0[ZIhPzJiaILzJIJ6KEOnbHz0bZRmei2JbH:gcJVucW6nc3PlcpQh[XO\|YYmsJGVEPTBiPTCyOUDPxE1w	MmjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MUC0OlYoRjJzOUGwOFY3RC:jPh?=
HepG2	MW\DfZRwfG:6aXPpeJkh[XO\|YYm=		MUK3NkBpenN?	MlvKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxiboXtZoVzKGmwY4XiZZRm\CCob4KgO\|IhcHK\|LDDJR\|UxKD1iMkWg{txONg>?	NYjwU5VxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|U1PzFpPkK2NVM2PDdzPD;hQi=>
BxPC3	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXG3NkBpenN?	MlSwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEeGDDN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJI1mfGixZDygTWM2OCB;IEK1JO69VS5?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7OUG1O{c,OjV4OUmxOVc9N2F-
MDA-MB-468	MoPmR5l1d3SxeHnjbZR6KGG\|c3H5		NH3QO\|E1QCCqcoO=	MonKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMkiuOVgh\|ryPLh?=	M1rJdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEC0PVc6Lz5zOUiwOFk4QTxxYU6=
MDA-MB-468	M3e4WGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVK0PEBpenN?	Mn7SR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMkiuOVgh\|ryPLh?=	NHjJPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwOlY3QCd-MkCxNFY3Pjh:L3G+
MDA-MB-468	M2HBR2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M2LwWlQ5KGi{cx?=	M4PQT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFI5NjV6IN88UU4>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexOkc,Ojh3OE[3NVY9N2F-
K562	NXfJVHhtS3m2b4TvfIlkcXS7IHHzd4F6			MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJ7LkCzJO69VS5?	NYPDZXNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlIzODJpPkG4OVYzOjB{PD;hQi=>
HeLa	M3TP[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYnwNoVHPzJiaILz	NWLWOVJ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCyPU46PiEQvF2u	MlXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MEK4NlcoRjJ4NkCyPFI4RC:jPh?=
HepG2	NEfWd4tEgXSxdH;4bYNqfHliYYPzZZk>		NH74bGE4OiCqcoO=	NYPvc4E{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDNyIN88UU4>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR6MkS3Okc,OTl2OEK0O\|Y9N2F-
HepG2	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		MXq3NkBpenN?	MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|Ah\|ryPLh?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl{NkG3N{c,OTl7Mk[xO\|M9N2F-
HepG2	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=			Mn\xR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iM{Cg{txONg>?	NEXTVXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m4NVQ3Oid-MUe5PFE1PjJ:L3G+
HepG2	M{O0NmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlLwO\|IhcHK\|	Mn\OR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFMxKM7:TT6=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MUGzNUc,OjF5NEGxN\|E9N2F-
HepG2	Mmj4R5l1d3SxeHnjbZR6KGG\|c3H5		MXO3NkBpenN?	NEX2TI5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOzBizszNMi=>	NGT1eok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki4PVU2QSd-MkK4PFk2PTl:L3G+
HepG2	NEfSR3dEgXSxdH;4bYNqfHliYYPzZZk>		M3T1d\|czKGi{cx?=	MmPxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFMxKM7:TT6=	NUPwV5dURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTZpPkK0PVQ3OjF4PD;hQi=>
SH-SY5Y	NGfsSGhEgXSxdH;4bYNqfHliYYPzZZk>		MoDPO\|IhcHK\|	NFHvSnpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFPDOVAhRSB\|MDFOwG0v	NYDU[GtrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OVkyQThpPkK5OVU6OTl6PD;hQi=>
HepG2	MmnOR5l1d3SxeHnjbZR6KGG\|c3H5		NV[0TpVjPzJiaILz	NIXLToFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOzBizszNMi=>	NYjNc\|F4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg2PDNpPkK0PFU5PTR\|PD;hQi=>
HepG2	NX3WXmZbS3m2b4TvfIlkcXS7IHHzd4F6		MUK3NkBpenN?	NH7BPYVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOzBizszNMi=>	M{nDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY{Lz5{N{G1OVQ3OzxxYU6=
HepG2	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		M3XnSlczKGi{cx?=	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBESzVyIE2gN\|Ah\|ryPLh?=	NYPuTIViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVE3PzVpPkK1O\|kyPjd3PD;hQi=>
HepG2	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NWfzW3ZKPzJiaILz	NWnwWFRbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOzBizszNMi=>	MmrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OEKyOlcoRjJ3MkiyNlY4RC:jPh?=
HepG2	NG\zfIREgXSxdH;4bYNqfHliYYPzZZk>		M12yT\|czKGi{cx?=	NV;4fWo3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDNyIN88UU4>	NYDTTpJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OVIyOzJpPkKxPFUzOTN{PD;hQi=>
HepG2	Ml7IR5l1d3SxeHnjbZR6KGG\|c3H5		M{PJS\|czKGi{cx?=	NWXIPY9ZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDNyIN88UU4>	NHewVVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[wPFY4PSd-MkK2NFg3PzV:L3G+
HepG2	M1fsZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkL1O\|IhcHK\|	NUDsb2loS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGNEPTBiPTCzNEDPxE1w	NVTwTYdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2OVQ{QTVpPkK3OlU1Ozl3PD;hQi=>
KB	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=			MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDifUBUWkJiYYPzZZktKEWGNUCgQUA{OC56IN88UU4>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjV4MkizNkc,OTZ3NkK4N\|I9N2F-
HepG2	MofzR5l1d3SxeHnjbZR6KGG\|c3H5		NXHTT\|dPOjRiaILz	Mk\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgNlQhcHK\|IHL5JI5mfXS{YXygdoVlKHWydHHr[UBie3OjeTygWGM2OCB;IEOxJO69VS5?	NEGwXXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0OVgyPid-MkOxOFU5OTZ:L3G+
K562	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=		NUX0dpVqPzJiaILz	NHu4NHpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OCB;IEOyJO69VS5?	NFXLbZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS4NlQ4Pid-MUm0PFI1PzZ:L3G+
K562	MmrQR5l1d3SxeHnjbZR6KGG\|c3H5		NUnxOHd3PzJiaILz	NULpN4NxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkh\myxdzDjfZRwdWW2comsJGlEPTBiPTCzNkDPxE1w	M1zKcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK2NVc{Lz5zOUmyOlE4OzxxYU6=
FM3A	Mkn5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MmHwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDNc5V{\SCvYX3tZZJ6KHS3bX;yJGZOO0FiY3XscJMtKEWFNUCgQUA{OiEQvF2u	MkX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7Nk[3OFYoRjFyOU[2O\|Q3RC:jPh?=
FM3A	NVTBOoJUS3m2b4TvfIlkcXS7IHHzd4F6			M{f2VWlvKH[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJI1idW2jcomgSm0{SSClZXzsd{whTUN3MDC9JFMzKM7:TT6=	NHfJZ249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkCzOlM3PSd-MUKwN\|Y{PjV:L3G+
FM3A	MkDzR5l1d3SxeHnjbZR6KGG\|c3H5			MoLKR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgcYFudWG{eTD0eY1weiCITUPBJINmdGy\|IILldJJme2WwdHnu[{BiKG2xZHXsJI9nKGixc4SsJGVEPTBiPTCzNkDPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTh3NUm3PEc,OTF6NUW5O\|g9N2F-
FM3A	M4XTRmN6fG:2b4jpZ4l1gSCjc4PhfS=>			M1jkVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KE[PM1GgcY92e2VibXHtcYFzgSClZXzsd{whTUN3MDC9JFMzKM7:TT6=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOzZ5OESxN{c,OTN4N{i0NVM9N2F-
FM3A	M2XCcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIO3[2Y1QCCqcoO=	NInNW\|JEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVTODIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhcW6lcnXhd4UhcW5iY3XscEBl\W6\|aYT5JIFnfGW{IES4JIhzeyxiRVO1NEA:KDN{IN88UU4>	NEjnc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES3PVkzPid-MUi0O\|k6OjZ:L3G+
FM3A	NHfyVIdEgXSxdH;4bYNqfHliYYPzZZk>			NHvtUY9Ed22yb4Xu[EB4[XNidHXzeIVlKG[xcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBHVTODIH3veZNmKG2jbX3hdpkh[2WubIOuJEwhTUN3MDC9JFMzKM7:TT6=	NVO2d\|NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0OFc6PjFpPkGwOFQ4QTZzPD;hQi=>
LNCAP	NY[0bGpwS3m2b4TvfIlkcXS7IHHzd4F6		MVy3NkBpenN?	Mmj2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxiboXtZoVzKGmwY4XiZZRm\CCob4KgO\|IhcHK\|LDDJR\|UxKD1iM{KuPFch\|ryPLh?=	M1vGfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO1OFcyLz5{NkGzOVQ4OTxxYU6=
HCT116	M{GxPGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYfTfmxnPzJiaILz	NECwZXpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFeVVEGgZZN{[XluIFnDOVAhRSB\|Mz63JO69VS5?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjN7OEWzNUc,OTJ\|OUi1N\|E9N2F-
KB	MV7DfZRwfG:6aXPpeJkh[XO\|YYm=		M4\0XVczKGi{cx?=	NHjoN49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBGTDVyIE2gN\|MvPyEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QTF5MkizK\|46QTF5MkizQE9iRg>?
KB	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		NELYPZk4OiCqcoO=	MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB\|NDFOwG0v	MmLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NlQoRjJ2OUCwO\|I1RC:jPh?=
CHO	Ml3oR5l1d3SxeHnjbZR6KGG\|c3H5			NI\ZTXZEgXSxdH;4bYNqfHliYXfhbY5{fCCFSF:gZ4VtdHNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|UvQCEQvF2u	NF;vOWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkizNlIzOid-Mk[4N\|IzOjJ:L3G+
KB	MoiyR5l1d3SxeHnjbZR6KGG\|c3H5			NIXVVmlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NEA:KDN3Lkm1JO69VS5?	NHraZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUewOVIzOCd-MkG3NFUzOjB:L3G+
MCF7	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		M4TpSFQ5KGi{cx?=	MoXCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|YvOSEQvF2u	Ml;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUK1OVQoRjF7OEmyOVU1RC:jPh?=
MDA-MB-231	M3H3PWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHf3bJQ4OiCqcoO=	NYTGfFJUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB\|Nj61N{DPxE1w	NFjubWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[wNlgzPyd-Mk[2NFI5Ojd:L3G+
NFF	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		NWT5PVViOyCmYYnz	MlzCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmZHKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOzdwMzFOwG0v	M3;ZRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG3NVcxLz5{M{GxO\|E4ODxxYU6=
MCF7	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		M3jRflQ5KGi{cx?=	MnjNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gN\|gvPDRizszNMi=>	NIPwb\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOFk4QSd-MUm4NFQ6Pzl:L3G+
MCF7	MluzR5l1d3SxeHnjbZR6KGG\|c3H5		NIDXSFU1QCCqcoO=	NFrpZo1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUCgQUA{QC52NDFOwG0v	NXS2ZWdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFY3PjhpPkKwNVA3PjZ6PD;hQi=>
p53+/- MCF7	M2TWSmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3jRTVQ5KGi{cx?=	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKHB3MzuvMUBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUCgQUA{QC52NDFOwG0v	NVvjfJI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1OlE4OjBpPkKwOVYyPzJyPD;hQi=>
MCF7	MlPVR5l1d3SxeHnjbZR6KGG\|c3H5		NYPpcoZ3PDhiaILz	M2rTVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDN6LkS0JO69VS5?	NYXQeZlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OTZpPkK4OVg3PzF4PD;hQi=>
Caco2	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXOyJIRigXN?	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjY3:yJINmdGy\|IHHmeIVzKDJiZHH5d{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyIE2gN\|gvPjdizszNMi=>	NH71cJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OFA4Pid-MkSxPFQxPzZ:L3G+
THP1	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=			NUDVdIVbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXEiSMTDj[YxteyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0NEDPxE1w	M4nuXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUixOFYzLz5zN{m4NVQ3OjxxYU6=
THP1	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MlPZO\|IhcHK\|	MoP3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWGhROSClZXzsd{Bi\nSncjC3NkBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTyfUwhUUN3MDC9JFQxKM7:TT6=	M1[wUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|gyLz5zOUe0PFc5OTxxYU6=
THP1	NHf3Z5ZEgXSxdH;4bYNqfHliYYPzZZk>		MWK3NkBpenN?	NUTy[Vl2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXEiSMTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhSWyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA1OCEQvF2u	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEe0O{c,OTl7MUS3OFc9N2F-
THP1	MoPxR5l1d3SxeHnjbZR6KGG\|c3H5		M4HyclczKGi{cx?=	MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUTHAyKGOnbHzzJJV{cW6pIIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYX\0[ZIhPzJiaILzJIJ6KG[ub4egZ5l1d22ndIL5MEBKSzVyIE2gOFAh\|ryPLh?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ\|OEi1OEc,OjB4M{i4OVQ9N2F-
HEK293	Mk\WR5l1d3SxeHnjbZR6KGG\|c3H5		NH7jTIg4OiCqcoO=	M1rOc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDRyIN88UU4>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd5NESyO{c,Ojh5N{S0Nlc9N2F-
NCH-89	NXO1WJlzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3PhbFQ5KGi{cx?=	NGPRbVZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPhdo12e3SrbnWtdoV{cXO2YX70JG5EUC16OTDj[YxteyCjc4Pld5Nm\CCjczDCdoRWKGmwY3;ydI9z[XSrb36gZYZ1\XJiNEigbJJ{NCCLQ{WwJF0hPDFwMjFOwG0v	M1nBW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{K5O\|M{Lz5{MEOyPVc{OzxxYU6=
HepG2	NH\hS\|BEgXSxdH;4bYNqfHliYYPzZZk>		M3TNPFQ5KGi{cx?=	NFvrZ2REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCORFigZZN{[XluIFfJOVAhRSB2Mz6wPUDPxE1w	MoHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OES0NlIoRjJ3Nki0OFIzRC:jPh?=
L6	M1zSWnRwgGmlaYT5JIF{e2G7			M2fQR3RwgGmlaYT5JIFo[Wmwc4SgdoF1KEx4IHPlcIx{NCCLQ{WwJF0hPDNwMTFOwG0v	NV;1dIJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFE6PDhpPkG5O\|gyQTR6PD;hQi=>
KB	NFi4ZolEgXSxdH;4bYNqfHliYYPzZZk>		NHLMbZM4OiCqcoO=	M1XDe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygR2M2OCB;IES0JO69VS5?	M1G5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEG0PFU4Lz5{MECxOFg2PzxxYU6=
MKN28	NXvVXopuSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWmyJIRigXN?	M2\Bd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVvONlgh[2WubIOgZYZ1\XJiMjDkZZl{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUA1PC52NDFOwG0v	NX\jSW1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFQxPzZpPkK0NVg1ODd4PD;hQi=>
NFF	NUTI[2xLS3m2b4TvfIlkcXS7IHHzd4F6			NH7tV5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPTkZiY3XscJMtKEmFNUCgQUA1Pi54MEig{txONg>?	MmHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEW0NFIoRjNyMkS1OFAzRC:jPh?=
J774	MkDlR5l1d3SxeHnjbZR6KGG\|c3H5		M{D0N\|czKGi{cx?=	MlixR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTlc4PCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMVk3KGGzdXXveZMhd26nIIPvcJV1cW:wIHPlcIwheHKxbHnm[ZJifGmxbjDhd5NigSxiRVO1NEA:KDR5LkKg{txONg>?	MoPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MUWyO\|koRjJ7MkG1Nlc6RC:jPh?=
HEK293	NED2V5ZEgXSxdH;4bYNqfHliYYPzZZk>		NIXaSog4OiCqcoO=	NXLaNIdoS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XJiQnz1[UBie3OjeTygTWM2OCB;IES4JO69VS5?	NGD6S\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG5NFg2Pyd-MkGxPVA5PTd:L3G+
MRC5	NV;aVIs5S3m2b4TvfIlkcXS7IHHzd4F6			MnG2R5l1d3SxeHnjbZR6KGGpYXnud5QhVVKFNTDj[Yxtew>?	MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzNk[3NVgoRjF5MU[2O\|E5RC:jPh?=
HeLa	Mk\uSpVv[3Srb36gZZN{[Xl?	NWPXRVROOTBidV2=	NGD4epAyKGi{	NGjVfZhUfGmvdXzheIlwdiCxZjDy[YFkfGm4ZTDvfJlo\W5ic4DlZ4lmeyCrbjDoeY1idiCKZVzhJINmdGy\|IHH0JFExKHWPIHnuJJBz\XOnbnPlJI9nKDFyIIXNJGN2S2x{IHHmeIVzKDFiaIKgZpkh\GmqeXTyc4V1cGmmaYXtJIR6\SCkYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZk>	MnXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEi3PFYoRjF7N{S4O\|g3RC:jPh?=
A673	M4W4VZFJXFNiYYPzZZk>			NYDM[4pteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	M4XwW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MUDxTHRUKGG\|c3H5			M2fle5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NWq5T45zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	M{Gw[JFJXFNiYYPzZZk>			NXfVU5l6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M3XCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MnjvdWhVWyCjc4PhfS=>			MlTPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NGjuWYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MlnmdWhVWyCjc4PhfS=>			NUPRSXI{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	Mlq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NFHaSmhyUFSVIHHzd4F6			M1zWfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	NUPScJB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NELFfm9yUFSVIHHzd4F6			NF7SSYtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	M{XUSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NWL4dZFJeUiWUzDhd5NigQ>?			MlT0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	Ml;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NIjlWIxyUFSVIHHzd4F6			NUG2V\|E5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	M1PVcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MnW0dWhVWyCjc4PhfS=>			NFPUR4JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NYjFSWtxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	Mn;ZdWhVWyCjc4PhfS=>			MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NIXRToU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HEK293	M1zBWWF2fG:yaHHnfUBie3OjeR?=	NWrHOmV5OTBidV2=	NHjZUlM5KGi{cx?=	NIqwSoRKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBxPjJibHX2[Ywh[XRiMUCgeW0h[W[2ZYKgPEBpenNiYomgbY1ufW6xYnzveEBidmGueYPpdy=>	M33GZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEixOVM3Lz5{OES4NVU{PjxxYU6=
HEK293	NHPiNVRCfXSxcHjh[5kh[XO\|YYm=	MojxNVAhfU1?	NU\mb3VXQCCqcoO=	NVLNdWVyUW6mdXP0bY9vKG:oIHH1eI9xcGGpeTDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVEN\|LUKgcIV3\WxiYYSgNVAhfU1iYX\0[ZIhQCCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	MkK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OEG1N\|YoRjJ6NEixOVM3RC:jPh?=
LNCAP	NIPVWoxHfW6ldHnvckBie3OjeR?=			M{n5c3Jm\HWldHnvckBqdiCJRmCg[ZhxemW\|c3nvckBqdiCqdX3hckBNVkODUDDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKHCuYYPtbYR{KGOxLXX4dJJme3OrbnegS2ZRKGGwZDDzbHJPSXNiYXfhbY5{fCCURW[tSXJD[mW2YTDmc4xtd3enZDDifUBkd22yb4Xu[EB1emWjdH3lcpQhOjRiaILzJJBwe3RvdILhcpNn\WO2aX;uJIFv\CCvZXHzeZJm\CB2ODDodpMheG:\|dDDkc5Nm	Ml;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{W0O\|EoRjJ4MUO1OFcyRC:jPh?=
SKBR3	NI\BfHJHfW6ldHnvckBie3OjeR?=			MX\S[YR2[3Srb36gbY4hT0[SIHX4dJJme3Orb36gbY4hcHWvYX6gV2tDWjNiY3XscJMhfHKjboPm[YN1\WRid3n0bEBxdGG\|bXnkd{Bkdy2neIDy[ZN{cW6pIFfGVEBidmRic3jSUmF{KGGpYXnud5QhWkWYLVXSRoJmfGFiZn;scI94\WRiYomgZ49ueG:3bnSgeJJm[XSvZX70JFI1KGi{czDwc5N1NXS{YX7z[oVkfGmxbjDhcoQhdWWjc4Xy[YQhPDhiaILzJJBwe3RiZH;z[S=>	NUPLO4I1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|U1PzFpPkK2NVM2PDdzPD;hQi=>
HepG2	M3:4N2Z2dmO2aX;uJIF{e2G7			NXnjNnluWmWmdXP0bY9vKGmwIFfGVEBmgHC{ZYPzbY9vKGmwIHj1cYFvKEincFeyJINmdGy\|IITyZY5{\mWldHXkJJdqfGhicHzhd41q\HNiY3:t[ZhxemW\|c3nu[{BITlBiYX7kJJNpWk6DczDh[4FqdnO2IGLFWk1GWkKkZYThJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHS{ZXH0cYVvfCB{NDDodpMheG:\|dD30doFve2[nY4Tpc44h[W6mIH3lZZN2emWmIES4JIhzeyCyb4P0JIRwe2V?	M1[zNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO1OFcyLz5{NkGzOVQ4OTxxYU6=
H460	M1TsdWFxd3C2b4Ppd{Bie3OjeR?=	M33me\|I2KHSxIEe1JJVO	NHjyNmgzPCCqcoO=	NH;Kb2pKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFi0OlAh[2WubIOgZZQhOjVidH:gO\|UhfU1iYX\0[ZIhOjRiaILzJIJ6KGGwbnX4bY4uXiC\|dHHpcolv\y2kYYPl[EBndG:5IHP5eI9u\XS{eR?=	NWDkWpJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVkyPTdpPkK1Olk6OTV5PD;hQi=>
HepG2	NGfRfHVHfW6ldHnvckBie3OjeR?=	NGP2eVk2OCC3TR?=	MYq2JIhzew>?	MWTS[YR2[3Srb36gbY4hdHm\|b4PvcYFtKGGlaXTp[olk[XSrb36gbY4hcHWvYX6gTIVxTzJiY3XscJMh[XRiNUCgeW0h[W[2ZYKgOkBpenNiYomgSGFRUS:ueYPvJJRz[WOtZYKgdoVlNWSxdXLs[UB{fGGrbnnu[{Bj[XOnZDDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpd{Bz\WyjdHn2[UB1dyClb370do9t	NWDyWYoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVc{OjBpPkK4NVk4OzJyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ZEBRA / p-S824 KAP1 ; PubMed: 28249048 PLoS Pathog HH514-16 BL cells were treated with chloroquine and harvested at different times post-treatment for immunoblotting with antibodies as indicated. p62 / LC3 ; PubMed: 26677873 Proc Natl Acad Sci U S A Antiautophagic activity of Lys01. Panc 10.05 cells were treated for 24 h with the indicated doses of chloroquine or Lys01 and were probed by Western blot.	28249048 26677873
Immunofluorescence	p-S824 KAP1 / ZEBRA ; PubMed: 28249048 PLoS Pathog HH514-16 BL cells were treated with chloroquine (CQ) or chloroquine plus KU-55933 (CQ+KU) and harvested at 24 hours followed by staining with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification. CD1d-β2m / LAMP1 ; PubMed: 20368272 J Immunol HEK293-CD1d WT cells were treated overnight with 20 μM of chloroquine (or vehicle). The cells were then fixed, permeabilized and stained with the anti-CD1d-β2m mAb (red), anti-LAMP-1 (green) and Hoechst (blue). The stained cells were then analyzed by confocal microscopy. SQSTM1 / MAP1LC3B ; PubMed: 29872540 Cell Discov Immunofluorescent images of astrocytoma SNB-19 cells treated with DMSO, emetine or chloroquine for 24 h, then stained with SQSTM1 protein (green), MAP1LC3B protein (red) and nuclei (blue).	28249048 20368272 29872540
Growth inhibition assay	Cell viability ; PubMed: 25521075 Br J Pharmacol A549 cells were treated with serial concentrations of chloroquine for 72 h, and Huh7 cells were treated with the same concentrations for 48 h. Tumour cell viability was determined by cell viability assay. Data represent means from at least three independent experiments ± SD.	25521075

Protocol

References

[4] Hideo Yasuda, et al. Am J Physiol Renal Physiol . 2008 May;294(5):F1050-8.

- Collapse

Solubility (25°C)

In vitro	Water	100 mg/mL (193.85 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Chloroquine diphosphate SDF

Molecular Weight	515.86
Formula	C₁₈H₂₆ClN₃.2H₃O₄P
CAS No.	50-63-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04443270	Not yet recruiting	Drug: Chloroquine phosphate	COVID-19	CMN 20 de Noviembre	July 27 2020	Phase 1
NCT04462367	Not yet recruiting	--	COVID19\|Coronavirus Infection\|Pregnancy Disease\|Severe Acute Respiratory Syndrome	Instituto Materno Infantil Prof. Fernando Figueira	July 1 2020	--
NCT04340544	Terminated	Drug: Hydroxychloroquine\|Drug: Placebo	COVID-19	University Hospital Tuebingen\|Robert Bosch Medical Center\|Universitätsklinikum Hamburg-Eppendorf\|Bernhard Nocht Institute for Tropical Medicine	April 22 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

ATM/ATR Signaling Pathway Map

Related ATM/ATR Products

Ceralasertib (AZD6738) ^New

Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
KU-55933 (ATM Kinase Inhibitor)

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/K_i of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.
VE-821

VE-821 is a potent and selective ATP competitive inhibitor of ATR with K_i/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.
KU-60019

KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.
Berzosertib (VE-822)

Berzosertib (VE-822, VX970, M6620) is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.
AZ20

AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.
CP-466722

CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.
ETP-46464

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Choose Your Country or Region

By Signaling Pathways

By product type

Chloroquine diphosphate